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ABSTRACT 
Acute myeloid leukemia (AML) is a clonal disease of immature hematopoietic 
cells. Treatment of AML patients is based on conventional chemotherapy and 
stem cell transplantation, but the majority of patients still suffer from relapse and 
poor overall survival. A growing body of evidence suggests that the bone marrow 
(BM) microenvironment plays an important role in protecting leukemic cells from 
drug-induced apoptosis, which consequently leads to accumulation of residual 
leukemic cells and eventual relapse. Although several factors are involved in 
leukemic cell-BM interactions, the exact mechanisms of these interactions and 
comprehensive knowledge of their impact on the activity of different drug classes 
is lacking. Better understanding of the molecular mechanisms of drug resistance 
could facilitate the development of improved treatment strategies, and means to 
monitor patients who are at risk for developing drug resistance. Modern 
technologies, such as RNA sequencing and proteomics, are widening our 
possibilities to learn more about the molecular basis of AML and to discover 
predictive biomarkers for therapy resistance. 
In study I, we evaluated the effect of stromal cell secreted soluble factors on ex 
vivo drug responses in AML. We comprehensively evaluated how mononuclear 
cells (MNCs) collected from AML patients respond to 304 different inhibitors in 
stromal cell-conditioned medium (CM) compared to standard cell culture 
medium. From this study, we discovered that the stroma-derived factors altered 
response to 12% (36/304) of the drugs. Amongst the drugs, sensitivity to BCL-2 
inhibitor venetoclax was significantly reduced by the stromal conditions. In 
follow-up experiments, we found that this effect could be overcome by inhibition 
of activated JAK/STAT signaling.  
 
In study II, we investigated gene expression profiles that were associated with 
resistance to BCL-2 inhibitor venetoclax. Ex vivo and in vitro analyses of AML 
showed that high expression of S100A8 and S100A9 calcium binding family genes 
correlates positively with venetoclax resistance. In contrast, BET (bromodomain 
and extraterminal) inhibitor OTX-015 acted synergistically with venetoclax in 
resistant AML cell lines and patient samples.  
 
In study III, our aim was to determine the applicability of proteins in biomarker 
discovery. We compared marker panels from proteomic and microarray 
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transcriptomic assays using reproducibility optimized test statistic (ROTS) in the 
context of AML dysregulated processes and networks. The analysis led to 
discovery of protein markers specific for AML using LC-MS/MS derived data. 
 
In summary, this thesis shows that JAK/STAT inhibitors can counteract BM 
stroma-mediated resistance to the BCL-2 inhibitor venetoclax.  Furthermore, we 
discovered a gene expression profile that correlates with ex vivo venetoclax 
resistance in AML and provide evidence of AML-related biomarkers from a 
proteomics dataset. 
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1 INTRODUCTION 
AML is a complex disease with a relatively small number of recurrent mutated 
genes compared to other cancers1,2. Improved understanding of AML 
pathobiology has led to advances in the development of targeted therapies specific 
for disease-causing mutations with less toxic treatment options now available for 
AML patients.  Despite the on-going revolution in AML therapy, development of 
drug resistance remains a key challenge for accomplishing long-term responses 
and possibly curing the disease3. Due to the remarkable plasticity, AML cells are 
capable of evading toxic effects of drugs through various escape routes that 
harness the body’s normal control mechanisms4.   
 
The interplay between AML cells and the BM microenvironment has been 
recognized as an important contributor to disease progression5. However, 
knowledge of the molecular mechanisms of this interaction in relation to therapy 
resistance remains inadequate, especially regarding new targeted therapies. 
Moreover, new biomarkers are needed for identifying patients who would benefit 
from small-molecule inhibitors with novel mechanisms of action beyond those 
inspired by genomics, such as B-cell lymphoma (BCL-2) inhibitors6. As new 
drugs make their way to the clinics and change AML treatment, it is important to 
discover indicators of sensitivity and primary resistance. Biomarkers could be 
used to design novel treatment strategies that can possibly overcome drug 
resistance and lead to permanent cures.  
 
In this thesis, our aim was to characterize tumor-stroma interactions, to identify 
predictors of ex vivo drug resistance, and to discover protein level markers for 
deregulated signaling networks in AML. Furthermore, high-throughput drug 
sensitivity and resistance testing was used to find drug combinations that could 
overcome stroma-induced drug resistance of AML patient samples. By integrating 
transcriptomic and ex vivo drug sensitivity data from AML patients, we identified 
biomarkers for BCL-2 inhibitor resistance. Finally, we evaluated the value of 
protein markers for AML biomarker discovery.  
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2 REVIEW OF THE LITERATURE 
2.1 Hematopoiesis  
Hematopoiesis is a tightly coordinated process, which generates over 100 billion 
blood cells every day7,8. The generated cells are made from a small pool of 
hematopoietic stem cells (HSCs) with the capacity to self-renew and 
differentiate.9-12 During hematopoiesis, HSCs lose their self-renewal capacity 
whilst giving rise to common progenitors of myeloid (CMP) or lymphoid lineage 
(CLP).13-15 Myeloid progenitors further differentiate into 
megakaryocyte/erythroid progenitors (MEPs) or granulocyte/macrophage 
progenitors (GMPs)14 through lineage commitment. MEPs form platelets and 
erythrocytes, while GMPs give rise to neutrophilic, eosinophilic, and basophilic 
granulocytes and monocytes/macrophages. CLPs give rise to cells of the lymphoid 
lineage including B and T lymphocytes, natural killer cells and dendritic cells15 
(Figure 1). Mature blood cells carry out vital functions in the body including 
immunity, tissue remodeling and oxygen transport. 
 
Several transcription factors regulate HSC formation and subsequent lineage-
commitment. The most important factors for HSC production are Runx1, 
SCL/tal1, LMO2 and GATA-2, whereas HSC self-renewal is controlled by Tel, 
Bmi-1 and Gfi-1. Importantly, specific AML-associated translocations are known 
to affect these transcription factors including TEL-RUNX1 t(12;21)16. Lineage 
commitment is influenced by transcription factors that promote specific lineage-
switches and factors that antagonize paralleling lineage17. As an example, GATA-
1 expression drives the erythroid/megakaryocyte differentiation from CMPs, and 
in parallel interferes with the PU.1 promoted granulocyte/macrophage lineage18. 
Full erythroid/megakaryocyte development is accomplished with the expression 
of FOG-1, a cofactor of GATA-119,20, whereas C/EBP together with PU.1 are 
important for myeloid differentiation21,22. Other key regulators of hematopoiesis, 
Ikaros and Pax-5, play a role in lymphoid23,24 and B-cell development25,26, 
respectively. 
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Figure 1. Hematopoietic cell differentiation. Long-term hematopoietic stem cell, LT-
HSC; Short-term hematopoietic stem cell, ST-HSC; common myeloid progenitor, CMP; 
common lymphoid progenitor, CLP; megakaryocyte/erythroid progenitor, MEP; 
granulocyte/macrophage progenitor, GMP.  Adapted from Orkin et al, Cell 200817. 
 
2.1.1 Regulation of hematopoiesis 
2.1.1.1 Bone marrow microenvironment 
HSCs reside in the BM niche, which governs their differentiation and 
quiescence.27,28 The BM niche is a unique milieu composed of various stromal cell 
populations, extracellular matrix, and a tight network of vasculature. The area is 
lined by osteoblasts that separate the marrow from mineralized bone28,29. Looking 
deeper into the cellular composition, we see that BM stromal cells are a mixture 
of cells that originate from mesenchymal stem cells (MSCs). These cells include 
osteoblasts, chondrocytes, adipocytes, fibroblasts and perivascular stromal cells 
including CXCL12-abundant reticular cells. Moreover, endothelial cells, 
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macrophages and nervous cells are considered as additional components of the 
BM stroma. The stromal cells secrete distinct growth factors and extracellular 
molecules such as glycosaminoglycans, glycoproteins and collagen that form the 
extracellular matrix30. The majority of HSCs exist in the highly vascularized 
endosteal region of the BM, in close proximity to sinusoidal vessels, which arise 
from arterioles31. The sinusoids form a reticular network through which mature 
blood cells are released to the systemic circulation.32 
HSCs are mobilized and retained in the BM through interactions with adhesion 
molecules such as integrins (VLA-4 and VLA-5)33, laminins34, CD4435, E-
selectins36,37, CXCL1238, immunoglobulin-like receptors39 and osteopontin40. 
Retention to BM depends on several cytokines, especially CXCL12 (or stromal-
derived factor 1, SDF-1) that binds to its receptor CXCR4 on HSCs.41,42 HSCs can 
be mobilized from the BM by targeting these interactions either with a CXCR4 
inhibitor (plerixafor) or by reducing the number of CXCL12 expressing stromal 
cells with growth factors such as granulocyte-colony stimulating factor (G-CSF).  
Interestingly, the sympathetic nervous system has also been reported to play part 
in HSC release from the BM through nerve fibers that form synapses on 
perivascular cells37. Apparently, the neural stimulus creates important circadian 
regulation on CXCR4 and CXCL12 expression and circulation of HSCs43. Non-
myelinating Schwann cells wrapping the sympathetic nerves have been described 
to control HSC quiescence by secreting transforming growth factor-? (TGF-?)44. 
Other cell types contributing to BM niche regulation include adipocytes, 
megakaryocytes, macrophages and osteolineage cells. Contrary to earlier reports, 
the effect of osteolineage cells on HSC function appears to be indirect, as deletion 
of key HSC regulatory genes from osteoblasts was seen to have a minimal impact 
on their function41,45. 
2.1.1.2 Hematopoietic growth factors and signal transduction  
Hematopoietic growth factors are glycoprotein hormones that sustain 
hematopoiesis and functionality of hematopoietic cells via autocrine or paracrine 
signaling46,47. Hematopoietic growth factors include colony stimulating factors 
(CSF), interleukins (IL), and cytokines. According to in vitro studies, different 
stages of hematopoiesis are supported by specific growth factors. Stem cell factor 
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(SCF) and FLT3 ligand are important for maintaining HSCs and early progenitors, 
which can differentiate into specific lineages upon the body’s needs. On the 
contrary, the main growth factors for the lymphoid lineage are IL-7, IL-2, IL-5 
and IL-15; whereas granulocyte-macrophage-CSF (GM-CSF) and IL-3 are the 
most important factors for the myeloid progenitor differentiation48. Further down 
the myeloid lineage, thrombopoietin and erythropoietin are known to stimulate 
production of platelets and erythrocytes from MEPs, while macrophage-CSF (M-
CSF) and granulocyte-CSF (G-CSF) are the key factors for 
monocyte/macrophage49,50 and neutrophil differentiation51, respectively. The main 
growth factors and their functions are summarized in Table 1.  
 
Table 1. Function of the major hematopoietic growth factors (Adapted from Takei et al, 
Handbook of Hormones 2015)52. 
 
Ligand Receptor Major target Primary function 
EPO  EPOR Erythrocyte Red blood cell production 
G-CSF (CSF3, CSF-β)  CSF3R Granulocytes, neutrophils  Neutrophil production 
TPO (c-Mpl ligand)  TPOR Megakaryocytes, platelets  Platelet production, HSC 
maintenance 
GM-CSF (CSF2, CSF- 
α) 
CSF2RA/B Granulocytes, monocytes  Macrophage and granulocyte 
production  
M-CSF (CSF1) c-Fms (M-CSFRc, 
CSF1R)  
Monocytes, macrophages, 
osteoclasts  
Macrophage and osteoclast 
production 
IL-5 IL-5R/IL5RA Eosinophils, B cells, basophils  Eosinophil production 
IL-3 IL3-R Multilineage progenitors, 
basophils  
Differentiation of immature 
myeloid progenitors 
 
Hematopoietic growth factors regulate hematopoiesis by binding to their cognate 
receptors on target cells. Most growth factors signal through type I receptors of 
the cytokine receptor superfamily, which are recognized by four cysteine motifs 
of the extracellular domain53,54. Compared to other receptors, cytokine receptors 
form noncovalent connections with specific tyrosine phosphorylating enzymes 
called the Janus-associated kinases (JAKs). Upon ligand-induced receptor 
dimerization, JAK proteins (JAK1-3 and TYK2) induce a series of signal-
transducing tyrosine phosphorylations55. Briefly, receptor associated JAKs are 
trans-phosphorylated followed by phosphorylation of the receptor’s C-terminal 
tails. Subsequently, the phospho-tyrosines in the receptor form docking sites for 
Src-homology-2 (SH2) domain of signal transducer and activator of transcription 
(STAT) proteins. Upon binding to the receptor, STATs become phosphorylated 
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by JAKs, dimerize, and are released to the nucleus where they activate 
transcription of genes important for cell proliferation and survival56,57. Some of 
the most important genes induced by STATs are the MYC oncogene and the anti-
apoptotic B-cell lymphoma-extra large (BCL-XL)58,59. Depending on the cellular 
context, different members of the JAK and STAT families (STAT1-4, STAT5A, 
STAT5B, STAT6) are activated by specific growth factors or by different stimuli.  
 
STAT-mediated gene transcription is one of the key pathways for hematopoietic 
cell growth and development. However, JAKs also phosphorylate substrates of 
other major cell signaling pathways. The mitogen-activated protein (MAP) kinase 
pathway is a critical regulator of cell proliferation, whereas activation of the 
phosphatidylinositol 3 (PI3) kinase signaling leads to suppression of apoptosis60.  
 
The importance of JAK and STAT proteins on hematopoiesis has been 
demonstrated by genetic knockout studies on mice. Both Jak1 and Jak2 
deficiencies cause lethal phenotypes61; mice with Jak1 deficiency die perinatally 
and those with Jak2 die as embryos. Furthermore, loss of JAK3 is known to 
abrogate the development of T and B cells both in humans and mice62. Knockout 
of STAT genes also leads to failure in T cell differentiation and subsequent 
immunodeficiency phenotypes63.   
 
As the JAK/STAT pathway signaling has a central role in many biological 
processes, its functions are extremely well regulated. Three protein families, 
namely protein tyrosine phosphatases (PTPs)64, protein inhibitors of activated 
STATs (PIAS)65, and suppressor of cytokine signaling proteins (SOCS)66 are 
known to control JAK-STAT signaling through dephosphorylation and 
competitive binding to the phosphotyrosine binding sites. Despite these control 
mechanisms, point mutations in these signaling molecules can lead to various 
hematological and immune disorders. The most commonly found aberrations in 
hematological malignancies are point mutations in JAKs, of which gain-of-
function mutations of JAK2 and JAK3 are strongly associated with 
myeloproliferative disorders67-69. Importantly, JAK2 V617F mutations are found 
in >80% of polycythemia vera cases, and 50-60% essential thrombocythemia and 
idiopathic myelofibrosis patients69-71. The clinical relevance of JAK mutations in 
myeloproliferative disorders has inspired the development of JAK-targeted 
therapies. This has led to the approval of JAK1/2 inhibitor ruxolitinib for the 
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treatment of myelofibrosis72 besides other agents that are currently being tested in 
clinical trials.  
2.1.1.3 Apoptosis 
Hematopoiesis is a constant process that produces a vast amount of cells and 
therefore needs to be tightly controlled to maintain tissue homeostasis73. 
Apoptosis plays an important role for hematopoietic homeostasis by removing 
aged and damaged cells. Apoptosis can be initiated by two main pathways: 
through ligand binding to TNF-family death receptors (extrinsic pathway)74 or via 
secretion of cytochrome c from mitochondria (intrinsic pathway). Both pathways 
activate caspases, protease enzymes that through a sequence of events lead to cell 
shrinkage, chromatin condensation and formation of apoptotic bodies. Ultimately, 
apoptotic bodies are removed by phagocytes75. In the extrinsic pathway, the 
cytoplasmic “death domain” of the receptor transmits death signals upon ligand 
binding76. The best characterized mediators of extrinsic pathway are FasL/FasR 
and TNF-?/TNFR175.  
 
The intrinsic apoptotic pathway is triggered when suppression of death programs 
is lost, for example in nutrient deprived cells, or by stress stimuli caused by toxins, 
hypoxia and radiation. This leads to loss of mitochondrial membrane potential and 
subsequent release of pro-apoptotic proteins into the cytosol. Furthermore, pro-
apoptotic proteins such as cytochrome c activate the mitochondrial caspase-
dependent pathway75. Execution of apoptosis is controlled by members of the 
BCL-2 family that can alter mitochondrial membrane permeability. BCL-2 
proteins can be divided into three groups based on their structural units called 
BCL-2 homology (BH) motifs. Anti-apoptotic proteins contain motifs BH1-4, 
pro-apoptotic effectors contain regions BH1-3, whereas the so called BH3-only 
proteins contain the BH3 motif, which is shared with the anti-apoptotic and pro-
apoptotic proteins that they control77 (Figure 2).  
 
The first characterized anti-apoptotic protein was the oncogene BCL-2. It was 
discovered as part of the translocation t(14;18), associated with follicular 
lymphoma78. Later, other anti-apoptotic proteins (MCL-1, BCL-XL, BCLW, 
BFL1), pro-apoptotic proteins (BAX, BAK, BOK) and BH3-only proteins (BIM, 
BAD, BID, BIK, BMF, HRK, NOXA, PUMA) were discovered79. Importantly, 
overexpression of the anti-apoptotic proteins is one of the hallmarks of cancer that 
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provides growth advantage to cancer cells80.  The BH3 motifs of anti-apoptotic 
proteins form a docking site for specific pro-apoptotic proteins. As cancer cells 
carry high levels of the apoptosis initiating pro-apoptotic proteins, they are 
referred to as ‘primed for death’81. Triggering apoptosis in primed cells has hence 
been under intensive investigation for decades and has guided the development of 
BH3 mimetics6. These inhibitors replace pro-apoptotic proteins from cancer cells 
through competitive binding to the BH3 domain of anti-apoptotic proteins (Figure 
2). The extensive work has led to the U.S. Food and Drug Administration (FDA) 
approval of a BCL-2 selective inhibitor venetoclax for treating relapsed/refractory 
chronic lymphocytic leukemia (CLL) patients, and more recently for elderly AML 
patients in combination with hypomethylating agents82,83.   
Figure 2. Intrinsic apoptotic pathway and mechanism of action of BH3 mimetics. (A) 
Cellular stress such as toxins and radiation activate BH3-only proteins, which inhibit anti-
apoptotic BCL-2 proteins. This leads to activation and oligomerization of the effector 
proteins BAK and BAX at the mitochondria, driving mitochondrial outer membrane 
permeabilization (MOMP). MOMP allows the release of cytochrome c from the 
mitochondria into the cytosol, which through caspase activation results in apoptosis. In 
parallel, SMAC (second mitochondria-derived activator of caspase) represses inhibitor of 
apoptosis XIAP (X-linked inhibitor of apoptosis), which frees caspases and allows the 
activation of apoptosis. (B) Classification of the BCL-2 family proteins. (C) Mechanism 
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of action of BH3 mimetics such as venetoclax. Through binding to anti-apoptotic proteins 
such as BCL-2, the BH3 mimetics liberate pro-apoptotic proteins that can stimulate the 
activation of apoptosis. Adapted from Ashkenazi et al, Nature Reviews 20176, Leverson et 
al, Cancer Discovery 201783 and Konopleva et al, Cancer Discovery 201684.  
 
2.2 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is hematological malignancy that develops from 
myeloid progenitors. Upon a malignant transformation, these cells lose their 
differentiation potential, and proliferate rapidly in the BM, eventually impairing 
normal hematopoiesis. Disruption of normal blood cell counts lead to life-
threatening clinical symptoms such as anemia, thrombocytopenia and frequent 
infections48,85. AML is diagnosed when the amount of blast cells in the BM 
reaches >20% or specific cytogenic or molecular abnormalities are present (e.g. 
fusions RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA). The diagnosis is 
confirmed by morphological characterization of the malignant cells with light 
microscopy and by flow cytometry. Cytogenetic and molecular genetic analyses 
are also performed routinely48. Out of all acute leukemias (myeloid and lymphoid) 
diagnosed in adults, AML is the most common type with ~ 20, 000 cases per year 
in the USA86 and roughly 200 in Finland87. 
2.2.1. Origin and development  
The evolution of AML can be occasionally traced back to HSCs that acquire 
somatic mutations as a result of aging and exposure to different environmental 
risk factors88. Clonal evolution studies using next generation sequencing (NGS) 
methods have detected many of these mutations to be random “passenger” 
mutations that lack a role in the pathogenesis of AML. In contrast, specific 
mutations that halt cell differentiation and increase clonal expansion have been 
termed as “founder mutations”. These, so called type-II mutations occur in 
epigenetic regulator genes DNMT3A, TET2, ASXL1, IDH1/288-90 and splicing 
factor genes (SF3B1, SRSF2, U2AF1)91. In particular, epigenetic mutations are 
considered to be early founding events that may emerge even decades before the 
disease onset. Interestingly, 10% of healthy older individuals (> 65 years of age) 
harbor somatic mutations in the same epigenetic regulatory genes without 
dysplastic hematopoiesis92,93. This process of clonal hematopoiesis of 
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indeterminate potential has been associated with a modest risk of hematological 
malignancy and cardiovascular disease93,94. According to current understanding, 
the development of full-blown malignancy requires type-I “driver” mutations such 
as FLT3-ITD, which increase cell division. The necessity of complementing 
mutations is apparent from the fact that AML patients have on average three driver 
mutations at the time of diagnosis. Furthermore, as the disease evolves, the 
founder clone acquires cooperating mutations that give rise to subclones. As 
subclones carry different mutational burden, they contribute to the progression 
and relapse of the disease88,89,95.  
2.2.2 Role of the BM microenvironment in AML 
The BM microenvironment is believed to influence the initiation and progression 
of myeloid malignancies. The majority of supporting evidence comes from mouse 
studies, which have characterized interactions between leukemic cells and stromal 
cells. Specifically, the role of osteoprogenitors in leukemogenesis is supported by 
gene knockout studies and studies exploring the effect of constitutive gene 
expression. Intriguingly, deletion of the endoribonuclease Dicer1 gene from 
mouse osteoprogenitors was observed to induce the development of 
myelodysplastic syndrome (MDS) and in some cases AML in mice96. Loss of 
Dicer1 led to reduced expression of ribosome maturation factor Sbds, which is 
known to be mutated in some patients with Shwachman-Bodian-Diamond 
syndrome. Interestingly, this syndrome is characterized by BM failure and 
predisposition to MDS and AML. Moreover, direct deletion of Sbds expression 
from osteoprogenitors induced myelodysplasia. In another study, activating 
mutation of ?-catenin in mouse osteoblasts was seen to abrogate the 
differentiation potential of progenitor cells leading to development of AML97.  
 
Besides these findings from mouse studies, the role of stromal cells on leukemia 
induction in humans remain speculative. Indirectly, MSCs from MDS patients 
have been found to express lower levels of DICER1, DROSHA and SBDS 
compared to healthy controls98. In addition, 38.3% of MDS and AML patients 
were reported to accumulate ?-catenin in osteoblast cells with enhanced Notch 
signaling97 in support of the experimental models. One potential proof for the role 
of microenvironment in leukemogenesis comes from donor cell leukemia. In rare 
cases, allogeneic HSC transplantation (HSCT) may lead to development of 
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secondary leukemia99,100, which seems to suggest that changes in the BM 
microenvironment may induce disease to healthy cells. However, the impact of 
germline mutations and drug-induced changes in the stroma have not been ruled 
out.  
 
Leukemia cells interact with stroma and have been demonstrated to induce disease 
advancing changes in the microenvironment. Through secretion of angiogenic 
factors101 and proinflammatory cytokines leukemia cells create an inflammatory 
environment that supports their survival and concomitant loss of normal HSCs. In 
a recent study, AML cells were shown to degrade the endosteal vasculature 
leading to loss of stromal cells and osteoblasts in the endosteal BM region102. 
Furthermore, AML cells in the vasculature poor region were speculated to be more 
resistant to chemotherapy102. Subsequent vessel rescue in mice was seen to 
improve efficacy of chemotherapy, pointing out the importance of BM niche 
alterations for leukemia growth. 
2.2.3 Genomic landscape  
The genetic landscape of AML is highly heterogenous with less than one recurrent 
gene-fusion event per patient (e.g. PML-RARA, CBFB-MYH11 and RUNX1-
RUNX1T)103. Large sequencing studies have attempted to identify recurrent 
mutated genes in AML to refine prognostic stratification of the disease and to 
identify previously unknown mutational events. Based on the first landmark study 
of 200 adult AML cases by The Cancer Genome Atlas (TCGA) Research 
Network, disease-defining mutations were found in 23 genes of nine different 
gene-categories1. Each patient carried on average 13 mutations of which only five 
were in frequently mutated genes. Interestingly, this showed that the number of 
mutations in AML genomes is much lower than in other cancers2.  
 
A few years after the TCGA study, Papaemmanuil and colleagues classified 1540 
AML patients into 11 subtypes based on co-mutations104. This retrospective study 
led to the discovery of three new AML categories including chromosome-
spliceosome mutations (18%), TP53-aneuploidy (13%) and conditional IDH2R172 
mutations (1%)104. The genetic information from these NGS studies has deepened 
our understanding of AML genomics and has been incorporated into the World 
Health Organization (WHO) classification of AML. This scheme classifies AML 
into six main groups based on morphology and immunophenotypic, genetic and 
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clinical markers. The main groups of AML according to the updated WHO 
classification in 2016 are: 1) AML with recurrent genetic abnormalities, 2) AML 
with myelodysplasia-related changes, 3) therapy-related myeloid neoplasms, 4) 
AML not otherwise specified, 5) myeloid sarcoma, and 6) myeloid proliferations 
of Down’s syndrome105,106. 
2.2.4 Therapy 
Newly diagnosed AML patients are traditionally treated with cytarabine and 
anthracycline-based 7+3 induction chemotherapy (7 days of cytarabine plus 3 
days of anthracycline). It remains the backbone treatment for most AML patients 
and leads to complete remission (CR) in 60-85% of younger patients and in 40-
60% of older patients (>60 years of age)85. Treatment, however, may vary 
depending on patient-related factors, including advanced age107, performance 
status, co-morbidities107, and genetic factors. Genetic abnormalities strongly 
impact prognosis. Accordingly, the European LeukemiaNet (ELN) and the 
National Comprehensive Cancer Network (NCCN) have recently established risk 
groups for AML patients based on karyotype and mutational co-dependencies. 
Three risk groups are currently recognized, namely a) favorable, b) intermediate 
and c) adverse groups108.  
 
Recent approvals of targeted treatments have widened the therapy options for 
AML patients and certain patient groups are now eligible for an alternative first-
line induction depending on their mutational and prognostic risk profile. Since 
2017, favorable risk patients with core binding factor AML defined by 
rearrangements t(8;21) and inv(16)/t(16;16) that involve the RUNX1/RUNX1T1 
and CBFB/MYH11 genes, are eligible for treatment with gemtuzumab ozogamicin 
(GO), a monoclonal antibody targeting CD33 conjugated to calicheamicin109. 
Treatment of intermediate risk patients is also changing with the approval of a 
multitargeted kinase inhibitor midostaurin with activity against FLT3-TKD and -
ITD mutations. These mutations are found in approximately one third of all AML 
patients110. As FLT3 mutations are among the most common genomic alterations 
in AML, development of targeted FLT3 inhibitors has been a top priority in the 
post genomic era. After almost a decade of investigation, midostaurin in 
combination with chemotherapy was approved for the treatment of newly 
diagnosed FLT3 mutated patients by the FDA111,112. Relapsed/refractory FLT3 
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mutation positive AML patients may be treated with a newer generation 
FLT3/AXL inhibitor giltertinib, which was also recently granted approval by the 
FDA113. Another modification to the 7+3-based induction therapy is that older 
AML patients with adverse-risk karyotype (therapy- or MDS-related AML, 
secondary AML) are now eligible for treatment with a liposomal form of 
daunorubicin and cytarabine at a 5:1 molar ratio. The liposomal drug CPX-351 
has mainly been used as an induction treatment prior to allogeneic HSCT114.  
 
The B-cell lymphoma/leukemia 2 (BCL-2) inhibitor venetoclax was recently 
approved in combination with a hypomethylating agent or low dose cytarabine for 
treatment-naïve, unfit elderly AML patients. The approval was based on 
significantly improved overall survival in this high-risk patient group115. 
Venetoclax is a second generation BH3 mimetic that stimulates the intrinsic 
apoptotic pathway in leukemic cells through binding to BCL-2. This leads to 
subsequent release of pro-apoptotic proteins and induction of mitochondrial 
membrane permeabilization and apoptosis. The first generation BH3 mimetics 
(ABT-737 and ABT-263) were developed to target overexpressed anti-apoptotic 
BCL-2 family proteins BCL-XL, BCL-W and BCL-2 in hematological 
malignancies. The safety of these agents, however, was limited due to inhibition 
of BCL-XL in platelets and subsequent thrombocytopenia116. Intriguingly, 
venetoclax targets only BCL-2 and has been shown to have an acceptable safety 
profile in AML. While single agent venetoclax treatment of relapsed/refractory 
AML yielded only a modest response rate of 19% and a median complete 
remission of 48 days84, approximately 70% of treatment naï?e, elderly AML 
patients were shown to benefit from venetoclax in combination with 
hypomethylating agent115,117. This drug combination also had a favorable safety 
profile, with febrile neutropenia being the most frequent adverse side effect. Based 
on these results, venetoclax can now be used for the treatment of elderly, newly 
diagnosed AML patients, in addition to relapsed/refractory CLL patients with 17p 
deletion.  
 
Since the discovery of recurrent mutations in IDH1 and IDH2 in approximately 
20% of AML patients1,104,118,119, targeted therapies have been actively developed 
against these aberrations, which contribute to overproduction of the 
oncometabolite 2-hydroxyglutarate. The development work has led to the 
approval of IDH2 inhibitor enasidenib in 2017 by the FDA120, followed by the 
approval of IDH1 inhibitor ivosidenib in 2018121. Both therapies have been 
approved for the treatment of relapsed/refractory AML patients and have resulted 
 
 
 
 
26
in CR or CR with incomplete hematologic recovery (CRi) in 20% of patients 
treated with enasidenib and 30% of patients receiving ivosidenib. In May 2019, 
ivosidenib was approved as the first-line treatment for IDH1 mutated AML. 
Currently, both therapies are being explored further in clinical trials as single 
agents and in combination with other therapies, with the goal to achieve CR prior 
to allo-HSCT. 
2.3 Therapy resistance in AML  
Despite the recent improvements in the treatment of AML, the disease reappears 
in approximately 50% of younger patients (≤ 60 years) and 80-90% of older 
patients due to development of drug resistance122,123. In older patients, the long-
term survival with standard chemotherapy remains poor with only 10-15% 
reaching permanent cure108. Although HSCT can potentially prevent disease 
recurrence, only one-fourth of patients are eligible for intensive salvation therapy 
and transplantation124. Implementation of targeted therapies for the treatment of 
AML has also been challenging due to disease heterogeneity. As the disease is 
burdened by various co-occuring mutations, targeting one mutation or pathway 
has not resulted in major impact on the outcome. Responses to many of the 
treatments have remained short-lasting due to emergence of resistance. For these 
reasons, most relapsed AML patients ultimately die from the malignancy and there 
is substantial need for new treatment strategies to overcome therapy resistance. 
2.3.1 Mechanisms of drug resistance 
Drug resistance remains a major challenge for the treatment of AML. Resistance 
can arise either intrinsically prior to therapy due to pre-existing resistance-
mediating mutations or can be acquired as a consequence of therapy. 
Chemotherapy can enhance the selection and enrichment of the resistance bearing 
clones that lead to disease progression125. Other mechanisms that induce drug 
resistance in cancer cells include increased repair of DNA damage, epigenetic 
changes, resistance to apoptosis, modifications to drug targets and drug 
metabolism (intake, efflux and detoxification)126.  
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In AML, mutations to enzymes that phosphorylate cytarabine to its active form 
(cytarabine triphosphate) can lead to inactivation of the drug and subsequent 
cytarabine resistance127. Importantly, chemotherapy can induce development of 
cross-resistance to a range of drugs with different mechanisms of action. 
Multidrug resistance is mainly caused by overexpression of adenosine 
triphosphate (ATP) binding cassette (ABC) membrane transporters that increase 
cellular drug efflux128. Acquisition of mutations is another way for cancer cells to 
escape drug toxicity. One of the best-known examples of this mechanism is 
imatinib resistance in chronic myeloid leukemia (CML) with BCR-ABL. Point 
mutations and amino acid substitutions to the BCR-ABL kinase domain lead to 
structural changes in the protein, which compromise binding of imatinib to its 
target129. Similar to imatinib, mutations to the ATP-binding site and activating 
loop residues of FLT3 kinase domain lead to FLT3 inhibitor resistance in AML.  
Continuous exposure to drugs can also contribute to the development of acquired 
drug resistance by inducing mutations to the BCL-2 family genes. More 
specifically, these mutations may upregulate expression of anti-apoptotic proteins 
or reduce expression of pro-apoptotic proteins leading to BCL-2 inhibitor 
resistance. In cell line studies, resistance against BCL-2 inhibitor venetoclax has 
been associated with overexpression of anti-apoptotic BCL-XL and MCL-1. In 
addition, mutations to pro-apoptotic proteins, in particular the BH3 binding 
domain, have been shown to hinder venetoclax binding to its target130,131.   
Besides intracellular drug resistance mechanisms, extrinsic factors of tumor 
microenvironment may interact with leukemic cells and protect them from drug 
induced cell death. This phenomenon is showcased by the fact that AML cells are 
retained in the tumor microenvironment via soluble factor- or cell adhesion-
mediated interactions since blast cells express many of the same adhesion 
molecules as normal HSCs (e.g. CXCR4, VLA-4, CD44)5,132.  A well-known 
example of cell adhesion mediated resistance mechanisms is the 
CXCL12/CXCR4 pathway. The impact of this pathway on chemoresistance is 
shown with co-culture models, which have demonstrated upregulated expression 
of CXCR4 in AML cells after chemotherapy133,134. In this model, interaction of 
CXCR4 with CXCL12 expressing stromal cells and retention to the protecting 
BM was abrogated by CXCR4 inhibitors, which sensitized cells to 
chemotherapy133,134. The same was shown in murine models135. Moreover, 
increased CXCL12/CXCR4 and basic fibroblast like growth factor (FGF2) 
signaling has been shown to contribute to FLT3 inhibitor resistance in FLT3-ITD 
 
 
 
 
28
patient samples in addition to other survival pathways136-138. Examples of 
interactions of leukemic cells with the stroma that enhance chemotherapy 
resistance include VLA-4 and CD44 adhesion factor mediated binding of 
leukemic cells to the extracellular matrix component fibronectin139,140, and VLA-
4/VCAM-1 interaction with the stromal cells141. Likewise, VLA-4 negative 
patients are known to have favorable prognosis as they do not develop BM 
minimal residual disease induced by the leukemia-stroma interaction139. 
Interactions between leukemic cells and the stroma are summarized in Figure 3.  
 
 
 
 
 
 
 
 
Figure 3. Interactions of AML cells with the surrounding BM microenvironment. 
AML cells are retained in the tumor microenvironment via soluble factor- and cell 
adhesion-mediated interactions.  Endothelial cell, EC; mesenchymal stromal cell, MSC; 
vascular endothelial growth factor, VEGF; vascular endothelial growth factor receptor, 
VEGFR; C-X-C motif chemokine 12, CXCL12; C-X-C chemokine receptor 4, CXCR4; 
very late antigen 4, VLA-4; vascular cell adhesion molecule 1, VCAM-1. Adapted from 
Behrmann et al, Frontiers in Oncology 2018142. 
The BM microenvironment is enriched with many soluble factors including 
cytokines and chemokines. The role on these factors on drug resistance has been 
studied with cell line models. Interestingly, one study has reported that G-CSF 
may protect AML cells from c-KIT/ABL inhibitor (imatinib and nilotinib) 
mediated cell death143. Similarly, stroma-derived factors were shown to cause 
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imatinib-resistance by stimulating STAT3 phosphorylation and expression of 
anti-apoptotic proteins in CML cells. Furthermore, inhibition of paralleling 
JAK/STAT signaling by JAK1/2 inhibitor ruxolitinib was shown to restore CML 
cell sensitivity to tyrosine kinase inhibition144. Another recent study observed 
GM-CSF and IL-3 signaling through JAK, STAT5 and PIM kinases to rescue 
FLT3-ITD AML cells from FLT3 inhibition145. These and other clues indicate that 
the BM microenvironment blocks FLT3 inhibition through activation of 
redundant signaling pathways such as the RAS/RAF/MEK/ERK146 and 
PI3K/AKT/mTOR147,148 that lead to survival of FLT3-ITD AML cells and 
eventual relapse.  
2.3.2 Targeted therapies in clinical development 
Many novel compounds, which have been designed to target chemoresistant 
leukemic stem cells are currently being tested in clinical trials (Figure 4). 
Epigenetic compounds under development include histone deacetylation (HDAC) 
inhibitors, such as pracinostat, which is evaluated in combination with 
hypomethylating agents for older, unfit patients149. The novel hypomethylating 
agent guadecitabine has shown promising results in elderly AML patients and 
relapsed/refractory AML due to its improved resistance against cytidine 
deaminase degradation150,151. Bromodomain and extraterminal (BET) protein 
inhibitors that control RNA polymerase II and transcription of oncogenes are also 
under evaluation152. However, as a single agent, treatment with the BET inhibitor 
OTX-015 (birabresib) was reported to yield CR/CRi in only 3 out of 36 AML 
patients153. Potential combination therapies and possible predictive biomarkers 
indicating OTX-015 response need to be further investigated.   
 
As the majority of AML cases show constitutively activated receptor tyrosine 
kinase signaling, development of small molecule inhibitors against kinase 
activities has been of key interest during the past two decades. Most of the work 
has been directed towards FLT3 and KIT inhibitors, as alterations to these genes 
are frequent in AML. This has led to the development of new generation FLT3 
inhibitors with improved specificity against FLT3 compared to the first-
generation agents. Currently, three next-generation FLT3 inhibitors (crenolanib, 
quizartinib, giltertinib) are in phase III clinical trials for the treatment of AML154. 
Dasatinib, a multikinase inhibitor with activity against the KIT receptor tyrosine 
kinase (CD117) is also in a phase III clinical trial (NCT02013648) investigating 
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chemotherapy for the treatment of core-binding factor (CBF) AML155. KIT is 
highly expressed and commonly mutated in CBF-AML156, providing the rationale 
to add dasatinib to the current induction and consolidation chemotherapy regimen.   
 
Recently, immune-based therapies have been under careful scrutiny for AML 
treatment in hope of harnessing the body’s own immune system against leukemia. 
Current immunotherapies in clinical trials include 1) monoclonal antibodies 
targeting blast specific antigens and 2) T-cell response enhancing therapies such 
as bispecific T-cell engagers, immune checkpoint receptor antibodies and 
chimeric antigen receptor (CAR) T-cells157. Monoclonal antibodies have been 
developed against CD33 (e.g. lintuzumab) and CD38 (e.g. daratumumab). Other 
antibody-based approaches use antibodies to deliver toxic chemicals into 
leukemic blasts such as the CD33 drug conjugate gemtuzumab ozogamicin (GO) 
that is the only currently approved immunotherapy for AML158,159. Therapies in 
current clinical development include bispecific antibodies recognizing blast 
specific CD33160,161 and CD123162 antigens, conjugated with T-cell antigen CD3, 
in addition to antibodies blocking immune checkpoint receptors, namely the 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell 
death protein-1 (PD-1) on T-cells163,164.   
 
Lastly, therapeutic strategies are being developed to reverse the protective role of 
the BM microenvironment and its function as a sanctuary for residual disease and 
tumor cell survival. Most progress has been achieved so far with CXCR4 
inhibitors, as high CXCR4 expression is a prognostic indicator for poor outcome 
in AML165,166. Of these inhibitors, plerixafor has been approved for HSC 
mobilization in conjunction with G-CSF for lymphoma and myeloma167,168 and 
has been tested for AML patients in the first-line and salvage setting169-171. Despite 
their acceptable safety profile, larger randomized trials are needed for determining 
the benefit of CXCR4 inhibitors and for finding optimal combination regimens. 
Another significant advance in targeting the BM microenvironment has been 
made with the development of inhibitors against the adhesion molecule E-selectin. 
GMI-1271 is an E-selectin antagonist that disrupts blast cell binding to BM 
endothelial cells and subsequent activation of cell survival pathways172,173. Phase 
I/II clinical trials on relapsed/refractory and newly diagnosed, older AML patients 
obtained CR/CRi of 47% in combination with chemotherapy174,175. This led to a 
breakthrough therapy and orphan drug designation by the FDA and European 
Commission in 2017, and is currently followed up in an ongoing phase III clinical 
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trial to evaluate the efficacy of GMI-1271 plus chemotherapy in 
relapsed/refractory AML patients (NCT03616470).  
 
 
 
 
 
 
 
 
 
 
Figure 4. Novel therapy areas developed for the treatment of AML. Targeting therapy 
resistant leukemic stem cells is crucial for obtaining long term cure. Adapted from Short 
et al, Lancet 20183. 
2.4 Drug sensitivity testing in hematological 
malignancies  
Various drug screening methods have been developed to reliably assess the 
potency, selectivity, and efficacy of anti-cancer drugs ex vivo. Much of the 
developmental work has been done with leukemic cells due to the feasibility of 
harvesting and culturing cells collected from blood stream compared to solid 
tissues. The efficacy of anticancer drugs on leukemia cells can be assessed with 
assays that measure cell viability176. The most common assays are based on 
measurement of cell mass with the protein dye sulforhodamine B, detection of 
metabolically active cells through formation of a purple salt (MTT assay and 
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related assay formats), or release of ATP177. Out of these assays, ATP 
quantification most accurately quantifies the number of live cells. In addition to 
cell viability-based assays, also cell proliferation, apoptosis, and differentiation 
can be measured by flow cytometry (FACS), using different fluorochromes or 
fluorescent marker proteins. Flow cytometry-based assays benefit from the ability 
to monitor specific drug responses of particular cell populations, in comparison to 
assays measuring total cell killing. Recently, methods using high-throughput 
immunofluorescence microscopy for drug sensitivity testing have also emerged as 
a promising way to guide treatment selection for leukemia patients, although these 
methods warrant further investigation in larger patient cohorts178.  
 
The optimal readout and response parameters of different drug sensitivity testing 
assays remain to be standardized. Typically, half-maximal inhibitory or effective 
concentration (IC50/EC50) or area under the curve (AUC) measures have been 
used as a parameter to analyze drug response. These parameters, however, 
inaccurately represent differences in drug response patterns by for example 
neglecting maximal inhibition. Moreover, ex vivo culture conditions of primary 
cells require optimization as leukemic cells tend to differentiate, become 
senescent, or enter spontaneous apoptosis that can modify drug responses ex vivo. 
For example, cell culture oxygen concentration may impact cell metabolism and 
the production of reactive oxygen species altering the function of cells179. It is also 
important to consider the cytokine content and interactions with the BM 
microenvironment in high content drug testing assays as cells in vivo are in contact 
with many cell types. Improved co-culture methods that address the role of the 
microenvironment and immune system on drug responses are hence needed for 
better evaluation of the therapeutic outcome of drug treatment on patients.  
 
In recent years, high throughput drug screening platforms have been utilized for 
finding molecularly targeted treatments for leukemia patients. By combining 
measurements of drug sensitivity responses with molecular profiling, results from 
such testing have facilitated repurposing of approved drugs to other disease 
entities180. For example, ex vivo drug sensitivity testing led to identification of the 
tyrosine kinase inhibitor axitinib as a successful treatment option for CML 
patients with T315I mutation in the BCR-ABL1 fusion gene181. Regardless of the 
few success stories, more innovative ex vivo drug testing methods are needed, 
which better reflect the in vivo microenvironment, in order to more successfully 
translate results from ex vivo drug screening into patient care.  
 
 
 
33 
3 AIMS OF THE STUDY 
The overall aim of this thesis was to study the impact of the BM microenvironment 
on AML cells’ drug responses and to investigate mechanisms and predictors of 
drug resistance in addition to novel biomarkers for AML with the following 
specific aims: 
 
1. Evaluation of the effect of stroma-derived factors on ex vivo drug 
responses of primary AML cells.  
 
2. Determination of molecular mechanism and biomarkers of resistance to 
BCL-2 inhibitors. 
 
3. Identification of combination therapies to overcome ex vivo BCL-2 
inhibitor resistance of AML patient samples.   
 
4. Discovery of protein biomarkers linked to AML. 
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4 MATERIALS AND METHODS 
4.1 Study specimens 
4.1.1 Patients  
BM aspirates and peripheral blood (PB) samples used for the studies were 
obtained from AML patients after receiving their informed consent. BM aspirates 
from healthy donors were used as controls. Procedures were performed according 
to approved protocols (institutional review board of Helsinki University Hospital 
and Comprehensive Cancer Center) and in accordance with the Declaration of 
Helsinki.  
 
Study I included BM aspirates and PB samples (n = 26) from 21 AML patients. 
Drug sensitivity was assessed for 18 samples from 13 AML patients. Four of the 
samples were collected at the time of diagnosis whereas rest of the samples were 
from relapsed or refractory patients (10 relapse, 3 refractory). Other samples, not 
included in the drug sensitivity study, were used for mechanistic studies. In study 
II, RNA sequence derived gene expression profiles were compared with the drug 
sensitivity profile of 32 AML patient samples in order to identify associations with 
venetoclax response. Furthermore, mRNA-based gene expression analysis was 
done for samples from 112 AML patients and 4 healthy individuals for studying 
expression of the S100 family genes. In study III, datasets from the study of Foss 
et al182, including protein and transcriptomic data of four AML patients and six 
healthy donors, were reanalyzed for finding links to hematopoietic malignancies. 
In addition, 12 AML patient samples and one healthy control sample were used 
for validation experiments.  
4.1.2 Cell lines 
HS-5 human stromal cell line (American type culture collection) was used in study 
I for producing conditioned medium (CM). Cells were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS), L-glutamine and 
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penicillin-streptomycin until 70-80% confluent, following media replacement and 
collection after 72 h. Study II used leukemia cell lines MOLM-13, Kasumi-1, 
SKM-1, NOMO-1, SHI-1 and ML-2 (Deutsche Sammlung von Mikroorganismen 
und Zellkulturen Braunschweig, Germany). The cell lines were maintained in their 
respective media; SHI-1 cell line in IMDM medium with 20% FBS, the other cell 
lines in complete RPMI 1640 medium with 10-20% FBS. All the cell lines were 
maintained at 37 °C and 5% CO2.  
 
 
4.1.3 Animals 
The animal experiments in study I were approved by the Norwegian State 
Commission for Laboratory Animals. In order to study drug resistance to BCL-2 
inhibitors, female non-obese diabetic/severe combined immunodeficient ?IL2r?null 
(NSG) mice were inoculated IV with MOLM-13
luc AML cells and used as a 
murine AML model in the study. One week after tumor implantation, the mice 
were treated with 25 mg/kg venetoclax (intraperitoneally; vendor ChemieTek), 50 
mg/kg ruxolitinib (by mouth; vendor ChemieTek), venetoclax/ruxolitinib 
combination or a vehicle (n = 6 per group) for 3 weeks, 5 days a week. Tumor 
growth was monitored weekly by whole-body imaging (IVIS Spectrum Imager, 
PerkinElmer), detecting luciferin signal of the tumor cells.  
4.2 Sample processing 
Mononuclear cells (MNC) were isolated from BM and PB samples by density 
gradient separation (Ficoll-Paque PREMIUM, GE Healthcare). Cells were 
maintained in mononuclear cell medium (MCM, PromoCell), or in a mix of 25% 
HS-5 and 75% RPMI 1640 medium (study I). Excess cells were vitally frozen in 
FBS/10% DMSO and stored in liquid nitrogen until used for experiments.  
4.3 Drug sensitivity and resistance testing (DSRT) 
Drug sensitivity and resistance testing was done according to previously published 
method by Pemovska et al180 Briefly, drugs were pre-dispensed onto 384-well cell 
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culture plates in five different concentrations covering a 10,000-fold 
concentration range with an acoustic liquid handling device (Echo 550, Labcyte 
Inc.). AML cells were seeded to the drug plates with a Multidrop Combi peristaltic 
dispenser (Thermo Scientific). In study I, the drug testing was done in both MCM 
medium and 25% HS-5 conditioned medium/RPMI medium (CM), at a cell 
density of 4 x 105 cells/mL. After 72 h incubation at 37 °C, 5% CO2, cell viability 
was measured using the CellTiter Glo assay (Promega) that leads to cell lysis and 
release of ATP from viable cells. Luminescent signal proportional to the amount 
of ATP and metabolically active cells was then quantified with a PHERAstar plate 
reader (BMG Labtech). Dose response curves were generated based on the cell 
viability readouts with the Dotmatics software (Dotmatics Ltd.)  
4.3.1 Compound library 
A compound collection consisting of 304 FDA/EMA approved and 
investigational oncology drugs was used in the studies I and II. The compounds 
were obtained from the National Cancer Institute Drug Testing Program or 
purchased from chemical vendors. Based on instructions, the drugs were dissolved 
in DMSO or water and stored in a desiccator protecting them from humidity.  
4.3.2 DSRT data analysis 
Drug sensitivities were quantified with a drug sensitivity score (DSS), which 
corresponds to the modified calculation of the area under the curve, described 
previously by Yadav et al183. The DSS considers all four curve fitting parameters 
(IC50, slope, minimum and maximum response) in the calculation of AUC, in 
relation to the area between the 10% threshold and 100% inhibition. DSS values 
range between 0 and 50; 0 indicating less than 10% response and 50 the maximum 
inhibitory response. Leukemia specific drug responses were obtained by 
comparing DSS values of patient samples to mean DSS of healthy donor samples 
(selective DSS, sDSS). In study I, Ward’s algorithm and Spearman (drugs) and 
Manhattan (patients) distance measures were used for clustering the patient 
samples based on drug sensitivity differences between CM and MCM (deltaDSS). 
Comparison of DSS values with or without CM across samples was performed 
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using paired Student’s t tests. P-values <0.05 were considered statistically 
significant.  
4.3.3 Drug combination testing  
In studies I and II, drug combinations were tested by adding two drugs 
simultaneously at fixed concentrations to AML cells. Subsequently, cell viability 
data were analyzed with the Zero Interaction Potency (ZIP) model described by 
Yadav et al184. Synergistic drug combinations were determined by the ? synergy 
score, indicating the difference between the observed and expected response, and 
visualized by pseudo-coloring a 2-dimensional contour plot over the dose matrix.  
4.3.4 Co-culture assays 
MSCs from AML patients were seeded onto 96-well plates (Corning, Corning, 
NY) at a density of 1.5 x 10
5 cells/mL and let to adhere overnight, after which 
cells from AML patient were added directly to the stroma (1 x 10
5 cells/100 
mL/well) or separated by a 0.4-mm pore membrane (Corning). Drugs (0.1% 
dimethyl sulfoxide, 100 ?M benzethonium chloride, 300 nM ruxolitinib, 100 nM 
venetoclax) were added to the co-cultures and incubated with the cells for 48 
hours. AML cells were labeled with blast cell markers PE-Cy7-CD34 and BV605-
CD45 and viable cells were distinguished from apoptotic and dead cells with PE-
Annexin V and 7AAD antibodies (all antibodies from BD Biosciences). Flow 
cytometric analysis was done using the iQUE Plus instrument (Intellicyt, 
Albuquerque, NM) and ForeCyte software (Intellicyt).  
4.3.5 Prediction of genetic determinants of drug response 
In study II, a linear regression model185 was applied to identify genes associated 
with drug response (or failure to respond). To find the true relationship between 
gene expression change and drug sensitivity, we corrected confounding factors 
including age, gender, sequencing batch, RNA extraction method and RNA-
sequencing library preparation in the linear regression model. Differentially 
expressed genes with a false discovery rate (FDR) < 0.05 were considered 
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significant for drug sensitivity association. Unsupervised hierarchical clustering 
of samples and genes was done using the Ward’s method with Euclidean distance 
measure.  
4.4 Gene expression analysis 
RNA was extracted from AML cells using the miRNeasy kit (Qiagen; study I) or 
the NucleoSpin RNA kit (Macherey-Nagel; study II) and quantified using the 
Qubit RNA BR Assay Kit (Thermo Fisher). RNA integrity was assessed with the 
RNA 6000 Nano Kit and Bioanalyzer (Agilent). 
4.4.1 RNA sequencing 
RNA was depleted of ribosomal-RNA (Ribo-Zero™ rRNA Removal Kit, 
Epicentre), purified (RNeasy Clean-up Kit, Qiagen) and reverse transcribed to 
double stranded cDNA (SuperScript™ Double-Stranded cDNA Synthesis Kit, 
Thermo Fisher). RNA sequencing libraries were prepared using Illumina 
compatible Nextera™ Technology (Epicentre), size-selected and purified 
(QIAquick Gel Extraction kit, Qiagen). Transcriptomes were sequenced with the 
Illumina HiSeq2000 platform, using the TruSeq SBS Kit v3-HS reagent kit for 
paired end sequencing with 100 bp read length. 
 
RNA sequencing data were processed as described by Kumar et al186. Briefly, 
reads were corrected with Trimmomatic187 and after filtering, aligned to the human 
genome (GRCh38) using STAR188 and EnsEMBL v82 gene models. Picard was 
used for sorting the aligned reads and marking PCR duplicates. Feature reads were 
computed with SubRead189 and transformed to expression estimates with 
Trimmed Mean of M-values (TMM) normalization190. Genomic features with 
counts per million (CPM) value ≤1.00 were excluded.  
4.4.2 Real-time quantitative PCR analysis 
Complementary DNA was prepared from total RNA using SuperScript III 
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Reverse Transcriptase (Thermo Fisher). Real-time quantitative PCR (RT-qPCR) 
was performed on 10 ng of cDNA using iQ SYBR Green Super Mix (Bio-Rad, 
Hercules, CA, USA) in a CFX 96 instrument (Bio-Rad). The most stable 
reference genes were determined by CFX manager software from Bio-Rad and 
used for normalization purposes. Standard curves for all RT-qPCR reactions 
were included to determine specific primer efficiencies.  
4.5 Protein analysis  
4.5.1 Cytokine analysis 
RayBio C-Series Human Cytokine Antibody Arrays C2000 and C5 (RayBiotech) 
were used for analyzing the cytokine content of different media and BM 
supernatant fluids in study I. Signal was detected by using chemiluminescence 
and quantified with the Odyssey imaging system (LI-COR Biosciences).  
4.5.2 Western blotting  
MNCs were lysed in RIPA buffer (Cell Signaling Technology) containing 
additional 1 mM phenylmethylsulfonyl fluoride (PMSF). Following sonication 
and addition of Laemmli buffer, proteins were separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (12% gel, Bio-Rad), and transferred to 
nitrocellulose membranes (Bio-Rad). The membranes were blocked with 5% milk 
(studies I and II) or 5% bovine serum albumin (study III) for 1 h.  Detection 
antibodies used included: study I, anti-MCL1 (#4572), anti-BCLXL (#2764) (Cell 
Signaling Technology), anti-BCL2 (Dako), anti-β-actin (C4, sc-47778; Santa 
Cruz Biotechnology); study II, anti-calgranulin A (C-10, sc-48352), anti-
calgranulin B (MRP 1H9, sc-53187) (Santa Cruz Biotechnology), anti-β-actin 
(Merck); study III, DDX6/RCK, GPX1, fumarase (Cell Signaling Technology) 
and anti-GAPDH (Santa Cruz Biotechnology). Proteins were visualized with the 
Odyssey imaging system (LI-COR Biosciences). 
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4.5.3 Phospho-flow analysis 
After 20 minutes of cytokine stimulation (10 ng/mL; Peprotech), AML patient 
cells were fixed with Lyse/Fix Buffer (BD Biosciences) for 10 minutes and  
permeabilized with Perm Buffer III (BD Biosciences) for 30 minutes at -20°C. 
Cells were washed, stained with Alexa 647-anti-phospho-Stat5 (pY694), PE-
CF594-anti-phospho-Stat3 (pY705), BV421-anti-phospho-Akt (pS473), and PE-
anti-phospho-Erk1/2 (pT202/pY204; all antibodies from BD Biosciences), and 
analyzed on the iQUE Plus instrument (Intellicyt). Data were analyzed with 
Cytobank (Fluidigm).  
4.6 Pathway and network analysis 
In study II, Enrichr analysis tool and Ingenuity Pathway Analysis were used for 
gene function and network analysis of 349 genes negatively associated with 
venetoclax response. Enrichment analysis was done using Kyoto Encyclopedia of 
Genes and Genomes (KEGG) 2016 and Reactome 2016 gene set libraries. 
Similarly, Ingenuity Pathway Analysis was used in study III to visualize and 
predict downstream effects of candidate biomarkers from proteomic and 
transcriptomic datasets.  
4.7 Statistical analysis 
GraphPad Prism 5 (GraphPad, La Jolla, CA, USA) was used for statistical analysis 
in study I, whereas in study II, the analyses were performed with R version 3.3.3 
(2017-03-06) and Prism 7. Statistical dependence between two variables was 
assessed by Pearson’s correlation coefficient modeling. The Mann Whitney U test 
was used for analyzing differences between drug responses and gene expression. 
In study II, the Wilcoxon signed-rank test was applied to find significant 
difference in drug response between wild type and mutated AML patient samples 
for a given mutation. In study III, ROTS was used as the statistical data analysis 
procedure for analyzing common protein-transcript pairs from the study of Foss 
et al182. P-values below 0.05 and FDR below 0.05 were considered statistically 
significant. 
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5 RESULTS 
5.1 BM stroma-induced protection of AML cells (I) 
The BM microenvironment plays a role in supporting the survival of leukemic 
cells and influencing their responses to therapeutic agents. In study I, we aimed to 
develop a BM stroma-derived culture condition for high-throughput drug testing 
to evaluate the effect of BM microenvironment on drug responses in AML.  
5.1.1 Development of ex vivo culture conditions  
Ex vivo cell culturing conditions impact the survival and responsiveness of 
leukemic cells to therapeutic agents. Outside the body, leukemic cells are more 
prone to spontaneous, culture-induced apoptosis in the absence of growth factors 
and interactions of the BM microenvironment. Although leukemia cells can be 
supplemented with individual myeloid growth factors or combinations of them, 
their ability to support cell survival and feasibility in ex vivo experiments is 
limited191,192. Direct culturing with human stromal cell lines has been shown to 
improve AML cell viability193, however implementation of co-culture models to 
high-throughput testing with hundreds of drugs is challenging. Hence, in study I, 
we aimed to improve ex vivo culturing conditions of AML patient cells for high-
throughput DSRT and evaluated the impact of conditioned medium (CM) from a 
human BM stroma cell line HS-5 on AML cell viability.  
 
CM from the stromal cell line HS-5 was previously shown to support the 
proliferation of hematopoietic progenitor cells.191 In our study, we observed that 
25% CM combined with RPMI 1640 medium could significantly increase AML 
cell viability over three days culturing time compared to commercially available 
MCM. Furthermore, vitally frozen AML patient samples had an improved 
recovery in 25% CM after thawing, facilitating the use of frozen AML patient 
samples for ex vivo experiments (Figure 5A-B). 
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Figure 5. HS-5 CM supports survival of primary AML patient samples. (A) Freshly 
isolated or (B) vitally frozen AML cells were cultured in MCM or 25% HS-5 CM/75% 
RPMI mix for 3 days, and cell viability was assessed with the CTG assay.  
5.1.2 Stromal cell secreted cytokines stimulate STAT5 
phosphorylation and JAK/STAT signaling 
In order to identify the key growth factors in HS-5 CM that support AML cell 
survival, we analyzed the cytokine content of the CM with an antibody panel 
detecting 174 human cytokines. The stromal cell CM was detected to contain high 
levels of interleukin-8 (IL-8), GRO, IL-6, GM-CSF, MCP-1, MIP-3? and G-CSF 
(Figure 6A). To follow up on the physiologic relevance of the detections, we 
analyzed the cytokine content of a BM supernatant fluid from a healthy donor and 
a patient with AML, in addition to CM collected from patient derived MSCs. Most 
of the abundant cytokines in HS-5 CM were detected in BM fluid from AML 
patients and CM from MSCs, although at lower level compared to the HS-5 CM. 
Moreover, expression of corresponding receptors for the abundant cytokines 
indicated that these cytokines are likely to affect proliferation of AML cells. To 
further investigate these findings, we assessed the impact of stroma-derived 
soluble factors on cellular signaling activation. AML cells were stimulated with 
25% CM or with individual cytokines and the phosphorylation of STAT3, STAT5, 
ERK and AKT was measured in order to evaluate the activation of JAK/STAT, 
RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell signaling pathways, 
respectively. Compared to control conditions, CM induced rapid phosphorylation 
of STAT5. This effect was mimicked by the addition of GM-CSF or G-CSF to 
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cell culture medium, demonstrating the importance of JAK/STAT signaling 
pathway on leukemic cell survival (Figure 6B-C). 
 
Figure 6. BM stromal cell–CM increases JAK/STAT signaling in primary AML 
patient samples.? (A) Cytokine levels measured from HS-5 CM, CM from primary MSCs 
of an AML patient, and BM supernatant fluid collected from one AML patient and a 
healthy donor. Levels normalized to detections from RPMI 1640 medium. (B) Phospho-
flow analysis of phospho-ERK, phospho-AKT, phospho-STAT3, and phospho-STAT5 in 
AML patient cells treated with RPMI, 25% HS-5 CM, MCM, or RPMI supplemented with 
10 ng/mL of the indicated cytokines or a combination of all the cytokines for 20 minutes, 
showing stimulation of STAT5 phosphorylation. (C) Detection of STAT5 phosphorylation 
in AML cells from three patients after 20 minutes of stimulation with different media 
conditions or individual cytokines (10 ng/mL). Error bars represent standard deviation of 
duplicates.  
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5.1.3 Impact of stroma-derived factors on ex vivo drug 
responses of AML cells 
In order to evaluate the effect of BM soluble factors on response to different drug 
classes, we tested a collection of 304 inhibitors including 136 drugs (45%) 
approved by FDA/EMA, 103 (34%) investigational agents and 65 probes (21%) 
for 18 AML patient samples in the 25% CM condition. Drug responses were 
compared to results obtained from parallel testing in a standard MCM medium to 
extract the stroma specific effects on drug sensitivity. Drug response differences 
were evaluated by drug sensitivity scores (DSS), which were calculated from 
dose-response parameters.183  Overall, response to 12% (36/304) of the drugs was 
significantly affected (FDR < 0.05) by the drug screening condition as quantified 
by the difference of mean DSS (deltaDSS) for each drug in both conditions (Table 
2).  
Table 2. Analysis of the differences in AML patient samples’ sensitivity to drugs in HS-5 
CM or MCM medium.  
 
Drug Mechanism/ 
targets 
Included 
pairs 
Mean DSS 
CM 
Mean DSS 
MCM 
Mean DSS 
difference 
FDR 
Ruxolitinib JAK1/2 18 13,01 5,72 7,29 0,008 
Docetaxel Tubulin stabilizer 18 13,88 8,95 4,93 0,033 
Tofacitinib JAK2/3 18 4,94 1,04 3,91 0,003 
AZD1480 JAK1/2, FGFR 18 5,83 2,31 3,53 0,035 
Momelotinib JAK1/2 18  11,20 2,71 0,033 
Doxorubicin Topoisomerase II 17 5,36 7,54 -2,18 0,047 
Nutlin-3 Mdm-2 18 2,99 5,21 -2,22 0,021 
Chloroquine Antimalaria 18 7,63 9,85 -2,22 0,035 
Canertinib pan-ErbB 18 7,86 10,09 -2,23 0,014 
Belinostat HDAC 18 16,87 19,15 -2,28 0,049 
Fludarabine Purine analog 17 7,53 9,86 -2,33 0,020 
Etoposide Topoisomerase II 17 2,12 4,64 -2,52 0,033 
Panobinostat HDAC 18 20,33 22,93 -2,59 0,026 
UNC0642 G9a/GLP 17 2,92 5,95 -3,03 0,026 
Amonafide Topoisomerase II 18 3,08 6,73 -3,66 0,004 
AZ3146 Mps1  18 1,56 5,27 -3,71 0,026 
Pictilisib PI3K 18 7,82 11,65 -3,83 0,033 
Mitoxantrone Topoisomerase II 17 2,67 6,67 -4,00 0,026 
Daunorubicin Topoisomerase II 17 7,56 11,61 -4,05 0,003 
Teniposide Topoisomerase II 17 9,63 14,13 -4,50 0,047 
Quisinostat HDAC 18 16,90 21,66 -4,76 0,003 
Navitoclax BCL-2/BCL-XL 18 16,92 22,00 -5,08 0,020 
Omacetaxine Protein synthesis  18 25,11 30,23 -5,13 0,000 
Cabozantinib VEGFR2, MET, 
FLT3, TIE2, KIT, 
RET 
18 0,92 6,11 -5,19 0,033 
Valrubicin Topoisomerase II 17 8,06 13,29 -5,23 0,003 
Idarubicin Topoisomerase II 18 10,53 15,79 -5,26 0,026 
AZD7762 CHK1/2 18 5,27 12,31 -7,04 0,035 
Sunitinib Broad TK inhibitor 18 2,26 9,69 -7,44 0,026 
Ponatinib Broad TK inhibitor 18 5,16 12,66 -7,50 0,033 
Quizartinib FLT3 18 0,79 8,47 -7,67 0,035 
Foretinib Broad TK inhibitor 18 2,93 10,83 -7,90 0,033 
Venetoclax BCL-2 17 7,78 17,31 -9,52 0,008 
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The main drug classes, which were affected by the ex vivo screening conditions 
were tyrosine kinase inhibitors such as JAK inhibitors, topoisomerase II inhibitors 
and BCL-2 inhibitors. Most of these inhibitors were less potent at killing AML 
cells in the stroma-derived condition except the JAK inhibitors. Sensitivity to JAK 
inhibitors was enhanced across the AML samples in CM, which is in line with the 
soluble factor mediated JAK/STAT activation in AML. Moreover, samples 
harboring FLT3-ITD or CCDC88C-PDGFRB rearrangements were less sensitive 
to several TKIs targeting FLT3, VEGFR, PDGFR, ABL and KIT, when tested in 
CM (Table 2).  
5.1.4 Overcoming stroma-mediated drug resistance  
BCL-2 protein antagonists are a promising therapy option for the treatment of 
AML. Hence, we investigated the molecular mechanisms of CM-mediated 
resistance to BCL-2 inhibition (Figure 7A-B). First, we determined the effects of 
different cell culture conditions on the expression of pro-survival factors, and 
measured the expression of BCL-2 family genes after 48 hours of incubation in 
MCM and CM conditions. Cytokines contained in the CM decreased the 
expression of BCL-2 in AML cells, whereas BCL-XL expression was upregulated. 
This indicates that the factors secreted by stromal cells lead to downregulation of 
the target molecule of BCL-2 antagonists. Furthermore, AML cell survival in CM 
was driven by the anti-apoptotic protein BCL-XL rather than BCL-2 (Figure 7C).  
 
Subsequently, we wanted to better understand the impact of cytokines on drug 
resistance and tested the effect of abundant cytokines in CM to venetoclax 
response. Out of the tested cytokines, GM-CSF was identified to most effectively 
mimic the CM-induced resistance to BCL-2 inhibitor venetoclax (Figure 7D).  
Since GM-CSF is known to activate JAK/STAT signaling in leukemic cells194,195, 
we further studied the impact of this signaling pathway on venetoclax resistance 
by knocking-down STAT3 expression from a venetoclax resistant cell line. 
Increased sensitivity of STAT3 knockdown cells to venetoclax validated the 
potential contribution of JAK/STAT signaling to venetoclax resistance.  
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Figure 7. Stroma-based conditions reduce AML cell response to BCL-2 inhibitors. 
(A-B) AML patient samples show decreased sensitivity to BCL-2-specific inhibitor 
venetoclax and to BCL-2/BCL-XL inhibitor navitoclax in the HS-5 CM condition. (C) 
AML cell culturing in CM results in decreased BCL2 expression and induction of BCLXL 
expression in the cells. Bar plots represent the mRNA expression for BCL-2 genes after 
48 hours of incubation of AML cells (n = 6) in 25% HS-5 CM and MCM medium. Data 
are normalized against GAPDH expression and error bars represent standard deviation of 
at least two replicates. (D) Effect of AML cell culturing in RPMI, 25% HS-5 CM, or RPMI 
supplemented with 10 ng/mL GM-CSF or G-CSF on venetoclax response. The amount of 
live CD45+AML cells was analyzed by flow cytometry after 48 hours treatment with 100 
nM venetoclax. Error bars represent standard deviation of three replicates. ns, not 
significant. *P < .05; **P < .01.  
 
To follow up on the findings, we tested the ability of JAK1/2 inhibitor ruxolitinib 
to overcome stroma-induced resistance of AML cells to BCL-2 inhibition. 
Combination of venetoclax with ruxolitinib was synergistic in AML patient cells 
in CM and in a co-culture setting, either with direct contact to patient derived 
MSCs or separated with a pore membrane (Figure 8A-B). In contrast, inhibition 
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of JAK/STAT signaling was insufficient to overcome stroma-mediated resistance 
to FLT3 inhibitor quizartinib and no synergy was detected between ruxolitinib and 
venetoclax in the CM or MCM condition. 
 
As AML cells became resistant to BCL-2 mediated cell death when separated 
from stromal cells, this indicates that the stroma-derived soluble factors are 
adequate to cause venetoclax resistance.?Mechanistically, the combination of 
venetoclax with a JAK1/2 inhibitor ruxolitinib downregulated expression of the 
anti-apoptotic proteins BCL-XL, BCL-2 and MCL-1 (Figure 8C). 
Figure 8. JAK1/2 inhibitor ruxolitinib restores activity of BCL-2 selective inhibitor 
venetoclax against AML patient cells in stroma-based conditions. (A) Combinatorial 
treatment of AML cells with ruxolitinib and venetoclax is synergistic in 25% CM. Eight 
concentrations of the drugs were tested in the two conditions for 72 h after which cell 
viability was measured with the CTG assay and dose-response matrices of percent 
inhibition were generated for the indicated concentrations. Dose-response matrices of 
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delta synergy scores were calculated with the ZIP model. ???difference in %- inhibition 
compared with expected additive effect from the compound. (B) Amount of CD34+ AML 
cells after 48 h drug treatment with the indicated drugs (300 nM ruxolitinib, 100 nM 
venetoclax, or their combination) in RPMI, 25% HS-5 CM or with mesenchymal stem 
cells (MSCs) in a co-culture or a transwell setting, separated from stroma by a membrane 
with pore size of 0.4 ?m. Error bars indicate standard deviation from two experiments. (C) 
Protein levels of BCL-2 family members in AML patient cells after treatment with 300 
nM ruxolitinib (RU), 100 nM venetoclax (VE) or a combination of both drugs (COMB) 
in 25% HS-5 CM for 48 h. Membranes were visualized with the Odyssey imaging system.  
 
Finally, we evaluated the potency of venetoclax and ruxolitinib combination to 
target AML cells in a xenograft mouse model. NSG mice were inoculated with 
MOLM-13luc AML cell line expressing a luciferase marker. After leukemia 
engraftment, the mice were treated with venetoclax, ruxolitinib and a combination 
of both drugs in consecutive groups. Effects of the drugs on tumor burden were 
analyzed by bioluminescent imaging throughout the treatment period of three 
weeks, and one week after the treatment termination. At week four, the mice 
treated with the drug combination had a significant clearance of their leukemia 
burden, compared to single drug treated mice (Figure 9A-B). However, no 
improvement in the overall survival of the combination treated mice was 
accomplished due to toxicity issues. 
 
Figure 9. Combined blockade of JAK/STAT and BCL-2 pathways with ruxolitinib 
and venetoclax is synergistic in an AML xenograft mouse model. (A) Bioluminescent 
images of 24 NSG mice inoculated with luciferase expressing MOLM-13 cells that were 
treated with vehicle, venetoclax (25 mg/kg, i.p.), ruxolitinib (50 mg/kg, p.o) or both drugs 
for three weeks. Images were taken before starting the treatments (week 0), at weeks 1-3 
and one week after the treatments. (B) Mean bioluminescence recorded for each group at 
matching time points with panel A. Error bars represent standard error of the mean. 
**P<0.01, by Mann-Whitney test.  
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5.2 Identification of biomarkers for BCL-2 inhibitor 
resistance (II) 
Mechanisms and predictors of BCL-2 inhibitor resistance remain poorly 
understood even though most patients ultimately develop resistance to BCL-2 
inhibitor treatment. In study II, we used a machine learning method to integrate 
RNA sequencing results with ex vivo DSRT data for BCL-2 inhibitor venetoclax, 
in order to identify biomarkers associated with venetoclax resistance. In addition, 
we investigated potential combination strategies to overcome venetoclax 
resistance in AML patient samples.  
 
5.2.1 Molecular features of venetoclax-resistant AML patient 
samples 
 
To identify biomarkers for venetoclax resistance, we performed a linear regression 
analysis between gene expression and ex vivo venetoclax responses of AML 
patient samples. This analysis resulted in 601 differentially expressed genes, 
which significantly associated with venetoclax response (FDR < 0.05). Of these 
genes, 252 (41.9%) were positively and 349 (58.1%) negatively associated with 
venetoclax response. Genes with the highest positive and negative association 
with venetoclax response are shown in Table 3. Venetoclax sensitivity associated 
positively with five HOX family genes (HOXB5, HOXB6, HOXB7, HOXB8 and 
HOXB9). This finding is in line with a previous study by Kontro et al, who found 
HOX expression to predict response to BCL-2 inhibition196. Furthermore, 
venetoclax resistance was associated with a sub-cluster of 29 genes including 
three S100 family genes (S100A6, S100A8, and S100A9) that were among the most 
significantly associated genes (Figure 10). Interestingly, S100A8 and S100A9 are 
abundant proteins in myeloid cells197 and deregulation of these genes has been 
linked to progression of many tumor types. Pathway and network analysis of 
venetoclax resistance-associated genes using Enrichr analysis tool and Ingenuity 
Pathway Analysis showed many of them to be involved in function of the immune 
system and inflammation related responses. Interestingly, the S100 family genes 
S100A8 and S100A9 are also known to stimulate inflammatory responses and the 
production of cytokines198,199.  
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Table 3. List of genes with the highest positive and negative association with venetoclax 
response (FDR < 0.05). 
 
HIGHEST POSITIVE ASSOCIATION 
Gene name Fold change (log2) Average expression P-value adj. P-value 
HOXB9 0,230895634 -0,5630024 7,29E-05 0,01370862 
HOXB8 0,208259884 -2,1508601 7,73E-05 0,01370862 
HOXB6 0,162296426 1,79894795 0,00133111 0,03900134 
BEND6 0,157313606 0,98273025 1,15E-06 0,00144925 
FGF10 0,155394614 -3,604052 0,00147455 0,04068075 
HOXB5 0,139777143 0,24462293 0,00199805 0,04589318 
NEK10 0,131918155 1,33297499 0,00023522 0,02000502 
SPINK2 0,12579511 4,03385811 0,00221478 0,04848037 
HOXB7 0,117613084 -0,0900622 0,00185345 0,0439348 
MAMDC2 0,115312601 3,73650706 0,00040041 0,02495048 
DST 0,093132657 6,03682686 0,00128783 0,0383214 
WT1 0,089353945 2,59938381 0,00184551 0,04392958 
RASSF8 0,07550781 2,53779151 0,00078285 0,03265667 
SULT1C4 0,073229779 1,81123276 0,00114446 0,03712706 
FLT3 0,071766075 8,17642162 0,00090646 0,03436618 
RHOBTB1 0,071446448 3,60954454 0,00064464 0,02994137 
SCD5 0,069564151 2,75645708 0,00077833 0,03265667 
COL24A1 0,068920722 5,53448001 0,00031681 0,02249669 
MSI2 0,068393534 7,77198342 0,00020243 0,01907017 
IRGM 0,0636213 1,71969033 0,00029925 0,02189941 
HIGHEST NEGATIVE ASSOCIATION 
CMTM5 -0,189763303 -1,0881435 0,00016718 0,0184975 
NFATC4 -0,156212981 -2,5349857 0,00103499 0,03540044 
NFIB -0,150888586 -1,4106097 0,00156315 0,04101057 
EPPK1 -0,116444165 -0,1746154 0,00055435 0,02801968 
FCN1 -0,114642982 7,30275619 0,00012985 0,01738763 
PLBD1 -0,111085537 5,07154633 0,00171306 0,04196649 
ADM -0,111080178 1,88437456 0,00231486 0,04930133 
QPCT -0,109300097 2,40956148 0,00093683 0,03476507 
FPR3 -0,108781114 0,46757892 0,00235095 0,04959289 
C5AR1 -0,10854503 4,11062641 0,00223052 0,0484897 
VSTM1 -0,106950843 2,2834733 0,00025486 0,02083079 
SLC11A1 -0,106845245 4,28187867 0,00050002 0,0273639 
HK3 -0,104555137 5,60383777 0,00079705 0,03283197 
S100A9 -0,102862649 9,1781141 0,00056786 0,02823409 
SLC15A3 -0,101779214 2,50755844 0,00122558 0,03760769 
DLEU7 -0,101085099 0,10857368 2,35E-05 0,00994287 
S100A8 -0,099825883 8,44301442 0,00155839 0,04101057 
CPAMD8 -0,097142788 0,28517741 0,00113637 0,03712706 
FFAR2 -0,096801806 1,18349162 0,00208094 0,0470247 
NCF1 -0,096111624 4,11443888 0,00084509 0,03332352 
 
 
 
51 
Subsequently, we investigated association of venetoclax resistance and gene 
expression with somatic, nonsynonymous mutations. This analysis revealed a co-
occurrence of S100A8 and S100A9 overexpression and TET2 mutations with 
venetoclax resistance (Figure 10).  
 
Figure 10. Molecular features of AML patient samples resistant to BCL-2 inhibitor 
venetoclax. Somatic mutations, mRNA expression and ex vivo venetoclax response of 32 
AML patient samples. Top 100 significant genes associated with venetoclax resistance 
were clustered. Hierarchical clustering of samples and genes (mean centered log2 CPM) 
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was done using Euclidean distance matrix and complete clustering method. One of the 
major gene clusters consists of 29 highly upregulated genes (enclosed box) that strongly 
associate with venetoclax-resistance. Clustering of samples depicts three main groups. The 
bar plot displays venetoclax response (sDSS, selective drug sensitivity score) in matching 
AML patient samples in comparison to healthy donor samples. sDSS >5 indicates AML 
specific drug sensitivity.   
5.2.2 Elevated expression of S100A8 and S100A9 correlates 
with venetoclax resistance  
Expression of S100 family genes is known to be deregulated in various tumor 
types200-203 including AML. Intriguingly, high expression of S100A8 predicts poor 
survival in AML patients204. For these reasons, we were interested in the role of 
S100A8 and S100A9 as potential biomarkers for venetoclax resistance in AML. 
Analysis of the prevalence of mRNA expression of S100A8 and S100A9 in relation 
to other S100 family genes confirmed the highest expression of S100A8, S100A9, 
S100A4 and S100A6 in a cohort of 112 AML patient samples. Furthermore, this 
finding was supported by The Cancer Genome Atlas (TCGA) AML dataset1, in 
which 178 AML samples were divided into seven groups based on RNA 
expression profiles. Interestingly, one of the groups was detected to overexpress 
S100A8 and S100A9 along with other genes. This suggests that S100 family gene 
expression might be a marker for a specific gene expression signature that predicts 
higher likelihood of developing resistance to venetoclax treatment.  
To better understand the role of S100 family genes in venetoclax response, we 
assessed sensitivity of six AML cell lines to venetoclax after 72 hours exposure 
to the drug. Cell lines that were resistant to venetoclax, namely NOMO-1, SKM-
1 and SHI-1, displayed significantly upregulated expression of S100A8 and 
S100A9, whereas no expression was detected in the highly sensitive cell lines 
MOLM-13, Kasumi-1 and ML-2 (Figure 11A-B). To investigate potential 
mechanisms of S100A8/A9 mediated resistance to venetoclax, we analyzed the 
impact of high S100A8 and S100A9 expression on calcium release, as the 
S100A8/S100A9 complex is known to bind cytosolic calcium205,206. Calcium 
uptake by mitochondria promotes apoptosis by opening the permeability transition 
pore that leads to depolarization of the membrane and subsequent release of 
cytochrome c207. Previously, Spijkers-Hagelstein et al reported elevated 
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expression of S100A8 and S100A9 heterodimer to cause glucocorticoid resistance 
in MLL rearranged infant ALL cells208. Hence, we investigated the role of calcium 
binding on venetoclax resistance, and measured the amount of free-cytosolic 
calcium in venetoclax resistant and sensitive cell lines after 48 hours exposure to 
venetoclax. In the resistant cell lines, venetoclax-induced calcium release was 
lower compared to the sensitive cell lines, possibly impacting mitochondrial 
membrane permeabilization and induction of apoptosis (Figure 11C). 
Subsequently, we knocked-down S100A8 and S100A9 expression in venetoclax-
resistant cell lines by CRISPR/Cas9 genome editing technology. As deletion of 
S100A8 and S100A9 expression did not rescue venetoclax resistance, we 
concluded calcium binding to be insufficient to directly cause resistance to BCL-
2 inhibition. Thus, elevated expression of S100A8 and S100A9 genes can 
potentially serve as a prognostic marker or predictor of venetoclax resistance, but 
may not be a causal factor in the resistance. To elaborate the functional 
consequences of this finding requires further exploration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  S100A8 and S100A9 have a high expression in venetoclax-resistant cell 
lines compared with sensitive cell lines. (A) Dose response curves of AML cell lines 
after treatment with indicated concentrations of venetoclax for 72 h. Cell viability was 
measured using the CTG assay. (B) Western blot analysis of S100A8 and S100A9 proteins 
in venetoclax-sensitive (Kasumi-1, MOLM-13, ML-2) and venetoclax-resistant (NOMO-
1, SKM-1, SHI-1) cell lines. (C) Over-expression of S100A8 and S100A9 in venetoclax-
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resistant cell lines is associated with failure to release free-cytosolic Ca2+ after exposure to 
venetoclax (100 nM) for 4 h. Difference in the calcium release was statistically analyzed 
using the Mann-Whitney U-test. 
5.2.3 BET bromodomain inhibitor treatment restores sensitivity 
to BCL-2 inhibition  
In order to identify potential synergistic drug combinations that could overcome 
venetoclax resistance, we investigated correlation of S100A8 and S100A9 mRNA 
expression with response to 349 drugs for 35 AML patient samples. Integrated 
analysis showed significant positive correlation with S100A9 expression and 
sensitivity to a BET bromodomain inhibitor OTX-015 (Figure 12A). 
Subsequently, venetoclax was tested in combination with OTX-015 for AML cell 
lines and patient samples. Venetoclax resistant cell lines NOMO-1 and SKM-1, 
which express high levels of S100A8 and S100A9, reacted in a synergistic fashion 
to the combination treatment. Efficacy of the venetoclax/OTX-015 combination 
also correlated with the expression levels of S100A8 and S100A9 in primary AML 
patient samples. Seven samples (7/11) with high expression levels of S100A8 and 
S100A9 were sensitive to the drug combination, whereas in three out of four low 
expression samples, no synergy was observed (Figure 12B). These data 
demonstrate that OTX-015 confers or restores sensitivity to venetoclax in AML 
samples overexpressing S100A8 and S100A9. Mechanistically, the OTX-015 
treatment led to downregulation of BCL-2 and BCL-XL in the resistant cell lines, 
whereas BCL-XL was downregulated in some patient samples and BIM (encoded 
by BCL2L11) upregulated in others (Figure 12C).  
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Figure 12. BET bromodomain inhibitor OTX-015 restores venetoclax sensitivity in 
cells lines and AML patient samples that overexpress S100A8 and S100A9. (A) Drugs 
that show positive and negative correlation with the mRNA expression of S100A8 and 
S100A9. Dot size indicates the number of tested AML patient samples whereas color 
indicates significance of the correlation. (B) Delta synergy scores for the tested drug 
combination in AML patient samples expressing high or low-level of S100A8 and S100A9. 
Gene expression presented as log2 CPM values. A delta score > 5 indicates synergy. (C) 
Representative blots showing BCL-2 family proteins in AML cell lines and patient 
samples upon treatment with 100 nM venetoclax, 100 nM OTX-015 or their combination 
for 48 h.  
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5.3 Statistical evaluation of proteomic and 
transcriptomic profiles for biomarker discovery (III) 
In study III, our aim was to compare the value of protein level versus mRNA 
transcript level detections for AML biomarker discovery. By comparing matching 
label-free LC-MS/MS and gene expression microarray measurements from four 
AML patient and six CD34+ healthy control samples from the study of Foss et 
al182, we detected significant differences in the biomarker expression panels 
between the datasets (Figure 13). Proteome analysis revealed unique links to 
leukemic processes, demonstrating the value of label-free proteomic approaches 
for biomarker discovery in AML.  
 
 
Figure 13. Study design used for comparing proteomic and transcriptomic datasets. 
5.3.1 Proteomic and transcriptomic dataset detections 
Reproducibility Optimized Test Statistic (ROTS) analysis of differential 
expression between the AML patient and control samples revealed 61 significant 
(FDR < 0.05) detections (indicating positive correlation) from the proteomic 
dataset and 30 from the transcriptomic dataset for 639 matched protein-transcript 
pairs. Twenty-three of the detections were shared between the assays, representing 
an enrichment of upregulated detections (Figure 14). Detections from the protein 
dataset showed a wide range of up- and downregulated expression changes 
capturing subtle differences whereas in the transcriptomic data the expression 
levels were mainly strongly downregulated.  
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Figure 14. Patterns of protein and transcriptomic level detections. Average signal log 
ratios between four AML and six control samples for 639 matched protein-transcript pairs. 
Blue and red dots represent significant differential (FDR < 0.05) protein-level and 
transcript-level expression, respectively. Overlapping detections are marked in black. 
These detections are visualized with the Venn diagram. Reproduced with the permission 
from Wiley publishing group209. 
5.3.2 Links to hematopoietic diseases  
In order to evaluate the relevance of the detections as potential biomarkers for 
AML, we classified the significant detections from both datasets based on known 
links to hematopoietic diseases. From the 38 protein specific detections, nine 
proteins were involved in different leukemic processes. The transcriptomic 
detections, however, were mainly linked to disease development in general, 
except for one leukemia specific detection. Out of 23 detections common between 
the datasets, two were linked to acute leukemias (Table 4).  
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Table 4. Disease links for unique and shared protein and transcript-level detections (FDR 
< 0.05). 
 
Gene and protein identifiers Disease links (manual 
classification) Gene ID Protein name Protein Transcript 
FDR FDR 
UNIQUE PROTEIN DETECTIONS 
ACO2 Aconitate hydratase mitochondrial  0.036 0.085 
ACTN4 Alpha actinin 4  B: ovarian adenocarcinoma 0.000 0.091 
CANX Calnexin  0.029 0.086 
CALR Calreticulin  
A: expressed in cancers 
including AML 0.000 0.079 
CAT Catalase EC 1 11 1 6  
C: protects against oxidative 
damage 0.021 0.097 
C1QBP 
Complement component 1 Q subcomponent 
binding protein mitochondrial 
 
0.036 0.130 
CTSC Dipeptidyl peptidase 1 EC 3 4 14 1  0.047 0.314 
RAD50 DNA repair protein RAD50  C: DNA damage repair 0.038 0.071 
RPN2 
Dolichyl diphosphooligosaccharide protein 
glycosyltransferase subunit 2 EC 2 4 1 119 
 
0.028 0.077 
EPHB3 Ephrin type B receptor 3 EC 2 7 10 1  A: pre-B leukemic cell adhesion 0.020 0.065 
ALDOA Fructose bisphosphate aldolase A EC 4 1 2 13  0.020 0.138 
FH Fumarate hydratase mitochondrial  B: tumor suppressor 0.022 0.068 
GSN Gelsolin  
B: colon adenocarcinoma and 
melanoma cell migration 0.023 0.263 
PRKCSH Glucosidase 2 subunit beta  B: polycystic kidney disease 0.024 0.279 
HSPA8 Heat shock cognate 71 kDa protein  0.048 0.137 
HCLS1 Hematopoietic lineage cell specific protein  
A: expressed in early myeloid 
and erythroid lineage cells 0.022 0.239 
H1F0 Histone H1  0.036 0.070 
CAPG Macrophage capping protein  
B: Cholangiocarcinoma 
biomarker 0.000 0.132 
NAT10 N acetyltransferase 10 EC 2 3 1  C: protects against DNA damage 0.038 0.136 
GANAB Neutral alpha glucosidase AB EC 3 2 1 84  0.029 0.088 
SLC25A3 Phosphate carrier protein mitochondrial  0.033 0.093 
PEBP1 Phosphatidylethanolamine binding protein 1  0.046 0.129 
INPP5D 
Phosphatidylinositol 3 4 5 trisphosphate 5 
phosphatase 1 EC 3 1 3 n1  
A: negative regulator of myeloid 
cell proliferation 0.027 0.098 
GP1BA Platelet glycoprotein Ib alpha chain  
A: associated with 
thrombocytopenia 0.000 0.106 
DDX6 
Probable ATP dependent RNA helicase DDX6 
EC 3 6 1  
A: involved in the t(11;14) 
translocation in B-cell 
lymphomas 0.034 0.075 
PA2G4 Proliferation associated protein 2G4 A: linked to CML signaling 0.024 0.091 
SET Protein SET  
A: associated with myeloid 
leukemia 0.030 0.095 
PDHB 
Pyruvate dehydrogenase E1 component 
subunit beta mitochondrial 
 
0.000 0.089 
G3BP1 
Ras GTPase activating protein binding protein 
1 EC 3 6 1 
 
0.000 0.228 
SAFB Scaffold attachment factor B  B: breast tumorigenesis 0.031 0.081 
SHMT2 
Serine hydroxymethyltransferase 
mitochondrial  
 
0.020 0.067 
BAT1 Spliceosome RNA helicase BAT1 EC 3 6 1 B: rheumatoid arthritis 0.037 0.133 
SMARCC2 SWI SNF complex subunit SMARCC2   0.021 0.075 
TXNDC5 Thioredoxin domain containing protein 5  0.000 0.086 
TOR1AIP1 Torsin 1A interacting protein 1  0.000 0.083 
TRIM28 Transcription intermediary factor 1 beta  0.000 0.092 
TRA2A Transformer 2 protein homolog  0.049 0.088 
WAS Wiskott Aldrich syndrome protein  
A: B-cell development and 
function 0.048 0.128 
UNIQUE TRANSCRIPT DETECTIONS 
CLIC1 Chloride intracellular channel protein 1  B: glioma. hepatocarcinoma 0.157 0.037 
CORO1A Coronin 1A  0.058 0.000 
DLST 
Dihydrolipoyllysine residue 
succinyltransferase component of 2 
oxoglutarate dehydrogenase complex 
mitochondrial EC 2 3 1 61 
 
0.083 0.000 
NNT 
NAD P transhydrogenase mitochondrial EC 1 
6 1 2  
C: protects against oxidative 
damage 0.104 0.000 
DEFA1 Neutrophil defensin  
C: increased expression in 
inflammatory conditions and 
cancer 0.084 0.000 
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PRMT1 
Protein arginine N methyltransferase 1 EC 2 1 
1 
A: increased expression 
associated with acute 
lymphoblastic leukemia  0.248 0.033 
STRADA STE20 related adapter protein  C: binds and activates LKB1 0.069 0.000 
COMMON DETECTIONS 
ACAA2 
3 ketoacyl CoA thiolase mitochondrial EC 2 3 
1 16 * 
C: deficiency associated with 
netropenia and 
thrombocytopenias 0.000 0.000 
ABHD14B 
Abhydrolase domain containing protein 14B 
EC 3 
 
0.000 0.000 
ATP5J2 ATP synthase subunit f mitochondrial  0.000 0.000 
ATP5O ATP synthase subunit O mitochondrial  0.025 0.038 
DDB1 DNA damage binding protein 1  
C: responsible for UV DNA 
damage repair 0.023 0.034 
GPX1 Glutathione peroxidase 1 EC 1 11 1 9  
C: protects against oxidative 
DNA damage 0.026 0.000 
HNRNPK Heterogeneous nuclear ribonucleoprotein K  B: pancreatic cancer 0.026 0.000 
LDHA L lactate dehydrogenase A chain  0.000 0.000 
CYB5R3 NADH cytochrome b5 reductase 3  0.000 0.000 
NCSTN Nicastrin * 
B: cancers and Alzheimer's 
disease 0.000 0.000 
PSIP1 PC4 and SFRS1 interacting protein  
A: found to be fused to NUP98 in 
one case of ANLL 0.000 0.000 
PRDX1 Peroxiredoxin  
C: protects against oxidative 
damage 0.000 0.000 
PRDX2 Peroxiredoxin 2 EC 1 11 1 15  
C: protects against oxidative 
damage 0.032 0.036 
PAFAH1B2 
Platelet activating factor acetylhydrolase IB 
subunit beta EC 3 1 1 47 
 
0.000 0.000 
ALDH1A1 Retinal dehydrogenase 1 * 
A: involved in retinoic acid 
biosynthesis and AML  0.000 0.000 
PRSS57 Serine protease 1 like protein 1 EC 3 4 21  0.000 0.000 
SOD2 
Superoxide dismutase Mn mitochondrial EC 1 
15 1 1  
B: hepatocellular carcinoma 
0.000 0.000 
TCP1 T complex protein 1 subunit alpha  0.000 0.000 
CCT6A T complex protein 1 subunit zeta  0.000 0.000 
TMED10 
Transmembrane emp24 domain containing 
protein 10  
B: Alzheimer's disease  
0.000 0.000 
TMEM173 Transmembrane protein 173  C: activates NF-kB pathway 0.000 0.000 
OCSTAMP Transmembrane protein C20orf123  0.000 0.000 
HADHA 
Trifunctional enzyme subunit alpha 
mitochondrial 
 
0.000 0.000 
???????????? ??????????? ????? ??????????? ????? ?????? ????????? ??? ??????? ??? ??????????????
????????????? ????????? ????????? ????????? ??????????????????????????????? ??????? ???????????
development in general. *. “all or none” biomarkers identified in the original study????
??????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????
 
Furthermore, we validated the expression of three proteins glutathione peroxidase 
1 (GPX1), fumarate hydratase (FH) and DEAD-box helicase 6 (DDX6) by 
Western blotting in a set of AML patient samples and one healthy control sample. 
The antioxidant enzyme GPX1 and tumor suppressor FH, which had not been 
previously linked to leukemia, were overexpressed in the tested AML patient 
samples compared to the healthy control sample validating the findings of Foss et 
al study (Figure 15A). The protein level of DDX6, however, was inconsistent 
between the AML samples in line with the known heterogeneity of AML patients. 
Further pathway analysis of the proteins and the significant detections from the 
proteomic and transcriptomic datasets with the Ingenuity Pathway Analysis 
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connected them to PI3K and ERK1/2 signalling proteins that are part of key 
dysregulated pathways in cancer (Figure 15B).  
Figure 15. Western blot analysis of three selected protein level detections and their 
connection to signalling pathways. (A) Western blot analysis of the indicated proteins in 
10 AML patient samples and one healthy donor sample. Intensity shown relative to 
integrated intensity of GAPDH. (B) Network analysis of the significant detections 
between AML and control samples constructed using Ingenuity Pathway Analysis 
software. Solid and dotted lines represent direct and indirect interactions, respectively. 
Reproduced with the permission from Wiley publishing group209.  
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6 DISCUSSION 
Genomic profiling has inspired the development of novel targeted therapies for 
AML. Targeting specific genomic alterations, however, has proven less successful 
than envisioned, mainly due to the development of drug resistance, which leads to 
clonal expansion of drug resistant clones and subsequent relapse of the disease. 
Hence, further understanding of the pathophysiological mechanisms of drug 
resistance is needed for finding personalized treatment options for AML.  
 
New technologies such as high-throughput proteomics and drug screening could 
facilitate the discovery of biomarkers and indicators of drug resistance to targeted 
therapies. In this thesis, we investigated stroma-mediated drug resistance 
mechanisms and protein biomarkers for AML. We demonstrate that stroma-
derived cytokines reduce BCL-2 inhibitor venetoclax mediated killing of AML 
cells. We provide evidence that inhibition of activated JAK/STAT signalling can 
re-sensitize venetoclax resistant AML patient cells and xenografts to venetoclax.  
 
Furthermore, we have shown that expression of S100A8 and S100A9 genes 
predicts resistance to venetoclax. Finally, parallel analysis of proteome and 
transcriptome profiling data of AML patient samples led to discovery of AML-
specific protein biomarkers. 
 
 
6.1. BM microenvironment mediated drug resistance 
in AML 
In study I, our objective was to facilitate personalized therapy of AML with ex 
vivo drug sensitivity and resistance testing (DSRT) method and thereby help the 
clinical translation of drug response data210. To meet this objective, we evaluated 
how stroma-derived soluble factors affect drug responses. We used BM-stroma 
derived medium to mimic conditions that are present in the BM, since the cancer 
microenvironment is known to protect leukemia cells from therapy-mediated cell 
killing. Our goal was to characterize microenvironment-mediated drug resistance 
across drug classes and to discover novel mechanisms of drug resistance.  
 
These goals are particularly important, since most elderly patients with AML 
develop refractory disease and relapse. Moreover, traditional ex vivo culture 
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conditions insufficiently mimic the BM microenvironment, thereby the results 
from preclinical drug testing studies do not correlate with responses observed in 
vivo.  We discovered that AML cells retain their viability better in the presence of 
stroma-derived growth factors, as compared to standard medium. Moreover, we 
found that ex vivo drug response to 12% (36/304) of the tested drugs was 
significantly different under exposure to BM stroma-derived medium.   
 
Difficulties in culturing and maintaining AML cells ex vivo211 restrict the accuracy 
of data derived from functional drug testing assays212. In our study, we used CM 
from the immortalized human stromal cell line HS-5 for testing ex vivo drug 
sensitivities of primary AML cells. Cytokine-enriched CM has been reported to 
induce the growth of myeloid colonies191. We discovered that stroma-derived 
growth factors induce resistance to inhibitors of topoisomerase II, BCL-2 and 
many tyrosine kinases (Table 2). Moreover, resistance to these inhibitors was 
undetectable in a standard MCM. Interestingly, the majority of AML patient 
samples developed resistance to conventional chemotherapeutic agents such as 
daunorubicin or idarubicin. However, another conventional chemotherapy agent, 
cytarabine, was not affected by the soluble stroma-secreted factors. Consistently, 
direct cell-to-cell contact between stromal cells and leukemic AML cells was 
shown to protect AML cells from cytarabine induced apoptosis193. In line with our 
findings, BM-derived soluble factors that are present in whole blood samples have 
also been shown to reduce the response of AML cells to topoisomerase II 
inhibitors213. 
  
Many receptor tyrosine kinase inhibitors, including FLT3 inhibitors, were less 
effective at killing AML cells in the presence of CM, as compared to standard 
medium. FLT3 inhibitors have been under active development for almost two 
decades214,215, since  FLT3 is one of the most frequently mutated genes in AML 
and it associated with poor prognosis110,216. Responses to FLT3 inhibitors are often 
transient due to their inability to eliminate minimal residual disease (MRD). The 
BM microenvironment has been reported to play an important role in the survival 
of FLT3 mutated AML cells undergoing FLT3 inhibitor treatment. Co-culture 
studies with stromal cells have indicated that soluble factors such as angiopoietins, 
GM-CSF, G-CSF, TNF and VEGF, IGF, EGF, and CXCL12 mediate the 
protective effect138,217. In line with these findings, stromal cells from quizartinib 
treated AML patients were showed to have increased expression of FGF2, which 
protected AML cells from FLT3 inhibition through activation of RAS/MAPK 
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signaling136. Interestingly, we detected high levels of GM-CSF and G-CSF in the 
HS-5 CM in our study, suggesting that these growth factors could potentially 
mediate FLT3 inhibitor resistance. In accordance, a recent study by Sung and 
colleagues reported GM-CSF and IL-3 to mediate resistance to FLT3 inhibitors145. 
Additional studies are needed to confirm potential relevance of GM-CSF for the 
development of FLT3 inhibitor resistance.  
 
Since GM-CSF and G-CSF induce JAK/STAT signaling, we tested whether AML 
cells could be re-sensitized to FLT3 inhibitors by simultaneously blocking JAK-
STAT signaling. The JAK1/2 inhibitor ruxolitinib, however, was unable to restore 
quizartinib sensitivity in the CM condition. This finding was inconsistent with 
earlier studies, which tested first generation FLT3 inhibitors with JAK 
inhibitors137,218,219. In addition to the JAK/STAT pathway, FLT3-ITD can also 
activate MAPK and PI3K/AKT signaling pathways 220, so it may be more relevant 
to target these pathways to overcome stroma-induced FLT3 inhibitor resistance. 
In support of this, Yang et al demonstrated that ERK activation, downstream of 
MAPK pathway, rather than STAT5 leads to quizartinib resistance in FLT3-ITD+ 
AML cell lines and patient cells217. Interestingly, these results were in line with 
our observations regarding the JAK1/2 inhibitor ruxolitinib. Hence, it appears that 
activation of STAT5 by the BM has an inconsistent role for the development of 
FLT3 inhibitor resistance137.  
 
Another drug class, which was ineffective in CM, was the BCL-2 inhibitors. 
Previous studies have shown that besides BCL-2 mutations, upregulation of anti-
apoptotic proteins and downregulation of pro-apoptotic proteins may induce 
resistance to BCL-2 inhibition77,221,222. The role of extrinsic factors on BCL-2 
inhibitor resistance in AML has not been fully characterized. We discovered that 
GM-CSF may confer venetoclax resistance in AML patient samples. Previous 
studies have shown that GM-CSF induces expression of the anti-apoptotic 
proteins BCL-2 and BCL-XL223. Consistently, BCL-XL expression was 
upregulated in AML cells cultured in CM, while BCL-2 expression was 
downregulated. Thus, the shift to BCL-XL mediated cell survival in CM could 
explain the loss in sensitivity to the BCL-2 specific inhibitor venetoclax, which 
has only modest affinity to BCL-XL. Similar to GM-CSF, IL-6 was shown to 
induce BCL-XL and MCL-1 expression in multiple myeloma cells224. Gupta and 
colleagues showed that IL-6 causes resistance to venetoclax and to the dual BCL-
2/BCL-XL inhibitor ABT-737 through redirecting the binding of pro-apoptotic 
BIM to MCL-1 instead of BCL-2225. We also tested the impact of IL-6 on 
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venetoclax sensitivity on AML cells, but concluded that IL-6 is insufficient at 
mediating the resistance alone. In the study of Gupta et al, MCL-1 dependency 
was reversed by targeting of JAK1/2 or MEK, downstream of IL-6 signaling 
pathways. Consistently, we found that JAK1/2 inhibitor ruxolitinib can restore ex 
vivo venetoclax sensitivity of AML cells in the CM and in a xenograft model of 
AML.  
 
Kurtz et al reported several synergistic drug combinations with venetoclax using 
unfractionated BM cells, meaning that both blast cells and stroma-derived factors 
were present226. Importantly, they validated efficacy of venetoclax and ruxolitinib 
combination in a cohort of 195 samples consisting of newly diagnosed and 
relapsed/refractory AML samples227. Intriguingly, a phase I clinical trial that 
evaluates the safety and tolerability of venetoclax in combination with ruxolitinib 
in relapsed/refractory AML patient samples recently started enrolling patients 
(NCT038740529). Future work will show whether this combination shows 
efficacy in vivo and which drug resistance mechanism may emerge in these 
patients. Further studies are also warranted for discovering potential gene 
expression signatures that could predict patients’ sensitivity to this combination.   
 
Physiologically more relevant ex vivo and in vivo models are important for 
modeling interactions of leukemia cells with the BM microenvironment. Although 
CM, derived from a stromal cell line HS-5, improved viability of AML cells and 
promoted their emerging resistance to BCL-2 and FLT3 inhibitors, other 
interesting possibility would be to culture cells in the presence of the patient’s 
own serum. This approach would also consider inter-patient heterogeneity. 
Similarly, mouse models using BM MNCs from patients rather than cell lines 
could potentially better maintain the critical features of cancer cells and their 
interactions with the microenvironment228,229. Although there has been some 
success in using patient derived xenografts (PDX) for identifying personalized 
treatment options230, the long latency of disease initiation and the highly variable 
efficacy of engraftment rate are the most important, limiting challenges with these 
models. Moreover, differences in the murine versus human microenvironment, 
secretion of cytokines and growth factors may impact results obtained from mouse 
models231. Based on these factors, the results of our study also need to be 
interpreted carefully, as we tested human AML cells in a murine BM 
microenvironment.  
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6.2 Biomarkers of BCL-2 inhibitor resistance 
The BCL-2 inhibitor venetoclax recently received FDA approval for the treatment 
of unfit AML patients in combination with hypomethylating agents or low dose 
cytarabine115. Despite this recent approval, there is little information regarding 
how patients will respond to this novel therapy. It is anticipated that most patients 
treated with venetoclax will eventually become resistant, which makes the 
identification of novel combinatorial treatments particularly important. In study 
II, our aim was to identify gene expression profiles or signatures linked to 
venetoclax sensitivity and resistance. Our analyses revealed that overexpression 
of S100A8 and S100A9 correlates strongly with venetoclax resistance. Moreover, 
AML patient samples with high S100A9 expression showed significantly 
increased sensitivity to BET bromodomain inhibitor OTX-015, which in 
combination with BCL-2 inhibitor venetoclax was highly synergistic towards 
venetoclax-resistant AML patient cells.  
Besides alterations in the expression of anti-apoptotic members such as BCL-XL 
and MCL-1, determinants of venetoclax sensitivity and resistance are being 
studied actively. Preclinical studies have suggested that AML cells with WT1 and 
IDH1/2 mutations have increased sensitivity to venetoclax196,232. The increased 
sensitivity of IDH1/2 mutated samples to venetoclax resulted from R-(2)-
hydroxygluatarate-mediated inhibition of cytochrome c oxidase that induced 
BCL-2 dependence233. Moreover, AML patients with SRSF2 and ZRSR2 
mutations are more likely to respond to venetoclax, whereas patients with PTPN11 
or FLT3-ITD mutations are less responsive233. A study investigating biomarkers 
predicting venetoclax sensitivity from 200 AML patient samples found that 
samples harboring KRAS, PTNPN11, SF3B1, and TET2 mutations are more 
resistant to venetoclax-mediated cell killing234. Interestingly, TET2 mutations 
cause DNA hypermethylation235 and have been connected with chemokine 
production and activation of inflammatory pathways236,237. Somatic 
mutation information from our cohort indicated that patients with TET2 mutations 
show higher expression of S100A8 and S100A9, and display reduced sensitivity to 
venetoclax, compared to patients with wild type TET2. Intriguingly, high 
expression of S100A8 and S100A9 has been suggested as a biomarker for 
inflammation238, as these proteins are involved in innate and chronic 
inflammation239. Based on a recent study, p38 MAPK induces inflammatory 
signaling and survival of AML cells and inhibition of p38 in combination with 
venetoclax leads to enhanced cell killing240. Taken together, these data suggest 
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that an inflammatory response may be linked to venetoclax resistance. Future 
studies should further explore the role of inflammation and inflammatory 
pathways in venetoclax resistance. 
In a subgroup of AML patients, S100A8 and S100A9 genes were found to be 
significantly overexpressed. This finding was supported by The Cancer Genome 
Atlas (TCGA) Research Network study, which included gene expression data 
from 178 AML samples1. Interestingly, three genes in addition to S100A8 
and S100A9, namely PSAP, NAGA and CYBB, were also upregulated in the 
venetoclax-resistant patient samples analyzed in our study. Moreover, S100A8 and 
S100A9 were also upregulated in venetoclax-resistant samples in a study by 
Kontro et al, who found that overexpression of HOX genes may predict venetoclax 
sensitivity196. Importantly, further analysis using data from the Beat AML 
collaboration validated significant negative correlation of S100A8 and S100A9 
expression with venetoclax sensitivity in 186 AML patients241. This indicates that 
a subgroup of AMLs with a specific gene expression pattern might be more prone 
to venetoclax resistance. 
Many preclinical studies are currently searching for optimal compounds that could 
be combined with venetoclax for durable drug responses. By applying machine 
learning, we found that S100A9 expression correlates with high BET 
bromodomain inhibitor (OTX-015) sensitivity. Interestingly, OTX-015 in 
combination with venetoclax was highly synergistic in a subgroup of AML patient 
samples overexpressing S100A8 and S100A9. Notably, Peirs et al found that the 
BET inhibitor JQ1 in combination with venetoclax synergizes in T-ALL xenograft 
models. Similar findings have been made in lymphoma242-244 and AML226. 
Recently, another BET family bromodomain inhibitor (ABBV-075) was shown to 
modulate apoptotic pathways and to synergize with venetoclax in AML patient 
cells, cell lines and a xenograft mouse model245,246. As a result, this combination 
is currently under evaluation in a phase I clinical study (NCT02391480). 
Mechanistically, BET inhibitors have been shown to downregulate anti-apoptotic 
proteins BCL-XL, BCL-2 and MCL-1. In our study, we observed that OTX-015, 
which binds to bromodomain motifs BRD2-BRD4 of the BET proteins, decreased 
BCL-XL and BCL-2 level in two cell lines expressing S100A8 and S100A9. In 
contrast, the AML patient samples had heterogenous expression of BCL-2 
demonstrating that other factors besides BCL-2 may influence venetoclax 
responses. Moreover, OTX-015 treatment led to upregulation of pro-apoptotic 
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BIM, indicating that the BET bromodomain inhibition may induce apoptosis. In 
support of these findings, upregulation of BIM has been shown after JQ1 and 
ABBV-075 treatment in AML cell lines, T-ALL cells, and in other cancers242,246-
248.  
Identification of patients that may benefit from investigational therapies such as 
venetoclax–OTX-015 combination remains challenging without robust 
biomarkers. In study II, we used gene expression profiling, ex vivo drug sensitivity 
data, and publicly available data sets to identify biomarkers of drug sensitivity and 
resistance. Further investigations, however, should be done with serial samples 
from venetoclax treated and clinically relapsed patients to validate our findings. 
Moreover, the predictive power of ex vivo drug testing should be evaluated more 
comprehensively, especially for epigenetic drugs such as OTX-015 that may 
require long periods of treatment before their efficacy can be accurately evaluated.  
6.3 Quantitative protein biomarkers in AML 
Improvements in proteomics approaches, such as label-free techniques and 
software tools have expanded the amount of information obtained from protein 
expression profiling in recent years249-253. However, the value of protein markers 
as opposed to DNA- and RNA markers for AML biomarker discovery is 
inadequately understood. Furthermore, experimental reproducibility and proper 
statistical testing remain challenges for protein biomarker studies254. In study III, 
our aim was to analyze how protein markers can bring novel insights into AML 
disease biology compared to markers derived from mRNA transcript profiling. 
The study was based on the re-analysis of matching proteomic and microarray 
datasets derived from AML and healthy control samples182 using the bioinformatic 
“reproducibility optimized test statistic” (ROTS) approach255,256.  
 
Correct statistical procedures are needed for identifying clinically relevant 
biomarkers from highly heterogeneous patient material. In particular, analysis of 
proteomics data poses specific challenges as the assays are susceptible to miss 
protein identifications and suffer from unquantifiable, low protein levels. 
Statistical problems have led to deficient marker lists that are difficult to validate 
clinically. In comparison, appropriate data analysis and different technical nature 
of gene expression data have helped to generate reproducible results257. To 
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consider these points, we used the ROTS approach for ranking protein and 
transcript detections in order of differential expression. The ROTS method is more 
robust than conventional ranking methods for analyzing different datasets, as it 
learns an adjusted test statistic for each dataset based on inherent distributional 
properties. On the contrary, conventional ranking methods use the same, 
potentially sub-optimal statistic for each experimental assay.  
 
The ROTS analyses resulted in 38 unique protein detections from the AML 
samples. Out of those, nine had connections to leukemia, in comparison to one 
transcript-level detection linked to hematological diseases. The original study of 
Foss and colleagues detected 17 differentially expressed proteins between AML 
patients and the control group. From those, retinal dehydrogenase, nicastrin, and 
3-ketoacyl CoA thiolase were potential biomarkers for AML after excluding 
proteins below the detection level in either group182.  These three biomarkers were 
also amongst the 23 common detections made in our study, expressed both on the 
mRNA and protein level. These results demonstrate that in-depth and quantitative 
statistical treatment of proteomic and transcriptomic data without excluding any 
low abundance proteins, provides an increased number of potential predictive 
biomarkers for leukemia. Furthermore, our analysis shows that proteomic 
profiling could yield more statistically significant and novel detections for AML 
in comparison to transcriptomic analysis.  
 
Interestingly, one of the significantly upregulated proteins (FDR<0.05) was 
GPX1, which protects cells from oxidative stress258. Since GPX1 had not been 
linked to leukemia, we validated its expression using immunoblotting and found 
overexpression of GPX1 in AML cells compared to healthy cells. The finding 
supported the results from the bioinformatic ROTS analysis. A similar study by 
Pei et al detected overexpression of GPX1 in CD34+ AML cells compared to 
healthy CD34+ cells259. This validated our novel findings made with the ROTS 
procedure that were missed out with a regular t-test (FDR = 0.24). 
 
The actual clinical value of protein markers for AML remains to be determined 
with different technologies and large patient cohorts. Currently, only a few 
relevant protein biomarkers have been discovered and verified clinically for AML. 
One such biomarker is the S100A8 protein that was discovered in a mass-
spectrometry study of 54 AML patient samples. In this study, specific protein 
signatures were discovered for different cytogenetic groups. Of the detected 
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proteins, S100A8 was the most relevant protein, which was subsequently verified 
to reliably predict poor prognosis in AML with high specificity and sensitivity204. 
Future studies are needed for establishing larger, clinically relevant protein 
biomarker panels for AML. This could improve the utility of protein biomarkers 
for classifying and monitoring patients as well as discovering individually tailored 
treatment options.    
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7 CONCLUSIONS 
In this thesis, we utilized high-throughput drug sensitivity and resistance (DSRT) 
testing assay to evaluate BM microenvironment mediated drug resistance in AML 
patient cells. In addition, we applied machine learning method for integration of 
RNA sequencing results with DSRT data to discover biomarkers associated with 
BCL-2 inhibitor resistance. Finally, ROTS-optimized statistics was used for 
deriving biomarker panels from proteomic and microarray transcriptomic assays 
and the results were compared in the context of AML dysregulated processes and 
networks. 
 
The main findings of this study are: 
 
1. BM stromal cells mediate protection of AML leading to BCL-2 inhibitor 
resistance, which can be overcome with the inhibition of JAK1/2. 
 
2. Elevated expression of genes encoding for calcium-binding proteins 
S100A8 and S100A9 correlates with acquired resistance to the BCL-2 
inhibitor venetoclax. In contrast, the BET inhibitor OTX-015 can reverse 
venetoclax resistance in AML patient samples overexpressing S100A8 
and S100A9. 
 
3. Application of new statistical detection method for protein biomarker 
discovery provided unique and significant AML markers compared to 
microarray-based transcriptomic assay. 
?
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